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N-methyl-D-aspartate (NMDA) receptor is a subfamily of the glutamate receptors in 
the central nervous system (CNS) that is involved in the mediation of many physiological 
activities such as learning and memory. However, overactivation of the NMDA receptors 
results in excitotoxicity that is often involved in the progression of neuronal cell death in 
diseases such as ischemic stroke. As such, NMDA receptors are tightly regulated by 
endogenous mediators.  
In particular, the serine protease, thrombin, which is observed in the astrocytes and 
neurons in the CNS, is involved in modulating the function of the NMDA receptors through 
the activation of the protease-activated receptor (PAR)-1. Direct interaction with the NMDA 
receptors by thrombin has yet been fully characterized and determined. The aim of the thesis 
is, thus, to investigate the possibility of direct interaction between thrombin and the NMDA 
receptors and the possible effects in the modulation of the NMDA receptors. 
 In this study, thrombin was observed to interact with the NR2B of the NMDA 
receptors from rat brain lysate (RBL) and synaptic plasma membrane (SPM) preparations. 
Based on epitope mapping and the sizes of the fragments (30 kDa fragment and 150 kDa 
fragment) observed, thrombin was hypothesized to cleave NR2B at the amino terminal 
domain (ATD). To identify the site of interaction of NR2B with thrombin, the NR2B ATD 
was expressed as a soluble recombinant fusion protein (MBP-ATD2B) and was subjected to 
thrombin treatment. N-terminal sequencing of the thrombin-cleaved product deduced the 
cleavage site to be Lys
318
 at the NR2B ATD. The cleavage site was further confirmed through 
the absence of cleavage on the MBP-ATD2B(K318A).  
Thrombin cleavage studies performed on cortical neuronal culture also demonstrated 
that thrombin could cleave NR2B expressed in heteromeric NMDA receptors complex. 
Through two-electrode voltage clamp (TEVC) recordings on Xenopus laevis oocytes 
viii 
 
expressing NR1/NR2B receptors, it was also observed that a reducing environment, one of the 
conditions of ischemic stroke, resulted in more efficient thrombin cleavage of NR2B, as 
demonstrated by a reduction in ifenprodil inhibition. Molecular dynamics simulation based on 
the NR2B ATD crystal structure also provided an insight into how a reducing environment 
exposed the Lys
318
 to the extracellular milieu, allowing for interaction with thrombin.  
 In the final part of the thesis, the various effects of the cleavage were investigated 
through TEVC recordings. In particular, the deletion construct, with the ATD region up to 
Lys
318
 removed (NR2B-ΔATD-K318) demonstrated an increase in the ifenprodil IC50 and a 
change in the EC50 of glycine and the efficacy of D-cycloserine when co-expressed with NR1. 
Interestingly, unlike ifenprodil, glycine and D-cycloserine are ligands binding to the NR1 
ligand binding domain (LBD) but not the NR2B ATD. These results suggested allosteric 
modulation of the ATD of NR2 on LBD of NR1 and the importance of the ATD in 
modulating receptor function. 
 Taken together, this study had discovered thrombin cleaved NR2B at a specific site at 
the ATD, which could lead to the alteration of NMDA receptor function. This study had 
provided an insight on the possible modulation of NMDA receptors through interaction with 
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1 Introduction       
1.1 Glutamate receptors 
Chemical synapses are the primary sites of communication between nerve cells. They 
are the specialized junctions where a presynaptic cell releases vesicles loaded with 
neurotransmitters to the receptors located on the adjacent postsynaptic cell (Lisman et al., 
2007; Chen et al., 2008c). There are excitatory and inhibitory neurotransmitters. Glutamate is 
one of the most common excitatory neurotransmitters and it binds to the glutamate receptors. 
Glutamate receptors are categorized into two groups namely the ionotropic glutamate 
receptors (iGluRs) and the metabotropic glutamate receptors (mGluRs). The mGluRs are G-
protein coupled receptors. Based on their amino acid sequence, intracellular coupling 
mechanisms and pharmacological properties, mGluRs are classified into three main groups, 
Group I (mGluR1 and mGluR5), Group II (mGluR2 and mGluR3) and Group III (mGluR4, 
mGluR6, mGluR7 and mGluR8) (Fig. 1.1) (Nakanishi, 1992; Niswender and Conn, 2010). 
The iGluRs are ligand-gated ion channels. They are structurally distinct from the 
mGluRs and exist as proteins containing three transmembrane domains. iGluRs are 
multimeric proteins made up of different subunit stoichiometry. They are pharmacologically 
categorized into three subclasses, (1) α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptors (GluR1-4), (2) kainate receptors (GluR5-7, KA-1 and KA-2) and (3) 
N-methyl-D-aspartate (NMDA) receptors (NR1, NR2A-D and NR3A and NR3B) (Fig. 1.1) 
(Dingledine et al., 1999).   
Unlike other ligand-gated ion channels, the NMDA receptors harbor a magnesium 
(Mg
2+
) binding site within the channel pore and binding of extracellular Mg
2+
 is strongly 
voltage dependent (Mayer et al., 1984; Nowak et al., 1984; MacDermott et al., 1986). As a 
result, activation of the NMDA receptors requires both ligand binding and partial relieve of 
the voltage-dependent Mg
2+ 
block by depolarization. Upon activation, the resulting calcium 
(Ca
2+
) flux triggers a variety of intracellular signaling cascades. Hence under physiological 
conditions, NMDA receptors play a pivotal role in many central nervous system (CNS) 
functions such as neurological development and in forms of synaptic plasticity that underlie 
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higher order processes such as learning and memory (Bliss and Collingridge, 1993; Maren 
and Baudry, 1995; Asztely and Gustafsson, 1996; Lau and Zukin, 2007; Yashiro and Philpot, 
2008). However, under conditions when the NMDA receptors are overactivated, they are 
implicated in neurological disorders such as ischemic stroke, brain trauma and chronic 
neurodegenerative diseases (Dirnagl et al., 1999; Arundine and Tymianski, 2003). Hence, 
the NMDA receptors have become the interest of many researchers in search for potential 
neuroprotective agents. 
 









1.2  Composition of NMDA receptors 
1.2.1  NR1, NR2 and NR3 subunits: regional and temporal expression and biophysical 
properties of NMDA receptors 
Three subunits, namely NR1, NR2 and NR3, have been cloned and studied 
(Hollmann and Heinemann, 1994; Ciabarra et al., 1995; Nishi et al., 2001; Chatterton et al., 
2002). The NR1 is encoded by one gene. From being barely detectable at embryonic day 14 
(E14), the mRNA of NR1 gradually increases during development until the third postnatal 
week. It decreases slightly to adult level and is detected in all neuronal cell types (Laurie and 
Seeburg, 1994a). The hippocampus, hypothalamus and the olfactory bulb have high 
expressions of the NR1 (Moriyoshi et al., 1991). The NR1 contains three alternatively spliced 
exons: exon 5 in the N-terminus (N1 cassette) and exon 21 (C1 cassette) and exon 22 (C2 
cassette) in the C terminus. C2 contains an alternative splice site such that part of the C2, 
including the stop codon, can be spliced out. This produces an alternative C2’ cassette and a 
new reading frame before the next stop codon is reached. The insertion and deletion of 
different combination of exons result in eight NR1 splice variants (Fig. 1.2). The splice 
variants give the NMDA receptors different biophysical properties. For example, variants 
lacking the N1 cassette insertion are more sensitive to proton (H
+
) and zinc (Zn
2+
) whereas 
variants containing the C1 cassette are modulated by the protein kinase C (PKC) (Tingley et 
al., 1993; Traynelis et al., 1995; Traynelis et al., 1998; Logan et al., 1999). Variants harboring 
the C2’ cassette have enhanced cell surface expression (Okabe et al., 1999; Standley et al., 
2000; Horak and Wenthold, 2009).  Expression of the splice variants is temporally distinct. 
NR1-1 and the NR1-4 account for the greater proportion of adult NR1 mRNA while the NR1-
3 mRNA is relatively scarce and is detected only at a low level during the postnatal stage 
(Laurie and Seeburg, 1994a). Splice variants expression is also regionally unique, for 
example, the NR1-(1-4)a and NR1-2 splice forms occur homogeneously throughout the brain 
gray matter but the NR1-(1-4)b are found primarily in the sensorimotor cortex, neonatal 
lateral caudate, thalamus, hippocampal CA3 cells and in the cerebellar granule cells (Laurie 
and Seeburg, 1994a; Standaert et al., 1994).  
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The NR2s are encoded by four different genes producing the four different subunits, 
NR2A-D. They are 55 to 70 % identical in sequence and are structurally related (Monyer et 
al., 1992). NR2 has to co-express with the NR1 to be functional NMDA receptors. The 
mRNA of NR2B and NR2D are found prenatally, while NR2A and NR2C are only detected 
near birth. NR2A-C peak around postnatal day 20 (P20) while NR2D peaks around P7. After 
which, all decrease to their respective adult level (Monyer et al., 1994). Most notably, there is 
a shift in the ratio of NR2B in a prenatal brain to NR2A in a mature adult brain (Sheng et al., 
1994; Yashiro and Philpot, 2008). There is also specific spatial expression for NR2 subunits. 
NR2A and NR2B are most abundantly expressed in the hippocampus CA1 and CA3 
pyramidal cells; NR2C are mostly found in the cerebellum and NR2D is prominently 
expressed in the thalamus (Wenzel et al., 1997). The NR2 subunits endow NMDA receptor 
complexes with distinct pharmacological and kinetic properties. For example, the order of 
potency of glycine follows NR2D > NR2C > NR2B > NR2A with the largest ratio between 
NR2A and NR2D (10-fold) (Chen et al., 2008b). In a similar order, the glutamate potency is 
the largest between the NR2A and NR2D (7-fold) (Laurie and Seeburg, 1994b; Erreger et al., 
2007). Efficacies for the partial agonist D-cycloserine also differ among the NR2 subunits, 
with NR2B and NR2C having the lowest and the highest efficacy respectively (Sheinin et al., 
2001; Dravid et al., 2010). The activation and deactivation of the NMDA receptors are also 
dependent on the NR2 subunit that is expressed. The peak open probability (POPEN) for NR2A 
differs from NR2B by four-fold, contributing to the differences in peak current density (Stern 
et al., 1992; Chen et al., 1999; Erreger et al., 2005; Gielen et al., 2009; Yuan et al., 2009a). 
NR2A and NR2B have a slow component of Mg
2+
 unblock that is not found in NR2C and 
NR2D. As a consequence, NR2C and NR2D respond more quickly to fast depolarization 
compared to NR2A and NR2B (Clarke and Johnson, 2006). The mean open duration is also 
dependent on subtypes. For example, NR2A has a overall mean open duration of 35.8 ms 
while that of NR2D is 1602 ms (Wyllie et al., 1998). Deactivation time is also subunit 
dependent in the following manner NR2A > NR2B > NR2C > NR2D (Vicini et al., 1998; 
Wyllie et al., 1998; Chen et al., 1999; Erreger et al., 2005). Besides modulating the 
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pharmacology and kinetics of the heteromeric NMDA receptors, NR2 also governs the 
differential binding to modulators and protein. For example, interaction with Zn
2+
 at the 
extracellular region is subtype specific with NR2A having the highest apparent affinity as 
evident by the lowest Zn
2+
 half maximal inhibitory concentration (IC50) compared to that of 
other subtypes (Fayyazuddin et al., 2000; Rachline et al., 2005). Intracellulary, NR2A and 
NR2B interaction with the PKC at the C-terminal results in the enhancement of the NMDA 
receptor-mediated Ca
2+
 flux while NR2C and NR2D interaction with the PKC results in 
suppression of Ca
2+
 flux (Grant et al., 1998). Trafficking of the NMDA receptors from the 
endoplasmic reticulum (ER) compartment to the cell surface membrane is also mediated by 
NR2 subunits (Qiu et al., 2009). Reduction/oxidation (redox) action is also dependent on the 
NR2 subtype identity (Kohr et al., 1994). Considering the differences among the subtypes and 
their specific temporal and regional characterization, the heterogeneity of the NMDA 
receptors plays an important role in mediating the numerous functions in the brain. In 
particular, the shift in the ratio of receptors containing NR2B and NR2A subunits, contributes 
to the developmental changes in synaptic plasticity and long term potentiation or depression 
in the brain (Ewald et al., 2008; Yashiro and Philpot, 2008; Cho et al., 2009).  
The NR3 are encoded by two genes, resulting in two subunits, namely NR3A and 
NR3B. NR3A and NR3B are closely related with 47 % identity in sequence homology 
(Chatterton et al., 2002). The NR3A expression level is high in the postnatal brain and 
decreases at P12 to adult level (Ciabarra et al., 1995; Sucher et al., 1995; Al-Hallaq et al., 
2002; Wong et al., 2002; Low and Wee, 2010). In adulthood, NR3A is detected 
predominantly in the thalamus, the nucleus of the lateral olfactory tract and the spinal cord 
(Ciabarra et al., 1995; Sucher et al., 1995). The NR3A also undergoes splicing at the C-
terminal with a 60 base pairs insertion, generating two variants, NR3A-1 (shorter variant) and 
NR3A-2 (longer variant). The NR3A splice variants are also expressed in a regionally and 
temporally specific manner (Sun et al., 1998). For the NR3B subunit, it starts its expression 
from P10-P14 and peaks at P21. The level of expression is maintained to adult stage (Fukaya 
et al., 2005). It is predominantly expressed in the motor neurons in the ventral horn of the 
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spinal cord and the facial and trigeminal nuclei of the brainstem in the adult nervous system 
(Andersson et al., 2001; Nishi et al., 2001; Chatterton et al., 2002; Bendel et al., 2005). It is 
also expressed in the forebrain and cerebellum (Wee et al., 2008). The NR3s are suggested to 
modulate the NR1/NR2 heteromers by reducing current responses and may also confer the 
NMDA receptors different sensitivity to Mg
2+
 ions (Das et al., 1998; Matsuda et al., 2002; 
Matsuda et al., 2003; Tong et al., 2008; Low and Wee, 2010).  
 
Fig. 1.2. Schematic representation showing the different splice variants of the NR1 
subunit. (Adapated from Pharmacological Reviews 1999, 51: 7-61) 
 
1.2.2 Receptor stoichiometry 
The NMDA receptors are heteromeric structures made up of the obligatory NR1 
subunit in combination with NR2 (NR2A-D) and/or NR3 (NR3A-B). There have been 
controversies with regards to the stoichiometry of the NMDA receptors. Earlier studies based 
on the pattern of single-channel conductance states and biochemical investigations have 
favored the concept that the NMDA receptors are pentameric structures (Brose et al., 1993; 
Premkumar and Auerbach, 1997; Hawkins et al., 1999). However, recent studies corroborate 
with the tetrameric structure. Using binomial analysis of the glutamate and glycine dose-
response obtained from three receptors populations expressed by different combinations of 
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wild-type NR1, NR2 and low agonist-affinity mutant NR1, NR2, it is hypothesized that the 
NMDA receptors follow a tetrameric structure with two glycine binding sites contributed by 
the NR1 and two glutamate binding sites contributed by the NR2 (Laube et al., 1998). The 
emergence of the heterodimer NR1-NR2A ligand binding domain protein crystal also fuel the 
inclination towards a dimer of dimers model (Furukawa et al., 2005). However, one concern 
with this model is the mismatch between the expected four-fold symmetry of the ion channel 
pore and the two-fold symmetry required by the dimer of dimers (Mayer, 2006). The recent 
tetrameric protein crystal structure of the GluR2 gives a glimpse on how this concern can be 
resolved. The symmetry mismatch is mediated by two pairs of conformationally distinct 
subunits. Guided by the crystal structure GluR2, luminescence resonance energy transfer 
(LRET) investigations and cysteine-crosslinking experiments, it is predicted that the NMDA 
receptor subunits exhibit a 1-2-1-2 pattern, indicative of a dimer of dimers pattern of a 
tetrameric structure (Sobolevsky et al., 2009; Rambhadran et al., 2010). Studies on the exact 
subunit composition of the native glutamate receptors are ongoing. Expression of di-
heteromeric (e.g. NR1/NR2A) or tri-heteromeric (e.g. NR1/NR2A/NR2B) is regionally and 
temporally specific (Sheng et al., 1994; Dunah et al., 1998; Tovar and Westbrook, 1999; 
Dunah and Standaert, 2003; Al-Hallaq et al., 2007; Brothwell et al., 2008). NR3 has also been 
observed to form diheteromeric receptors (NR1/NR3A or NR1/NR3B) and triheteromeric 
receptors (Ciabarra et al., 1995; Das et al., 1998; Perez-Otano et al., 2001; Chatterton et al., 




1.3 Modular structure of the NMDA receptors 
The general topology of the NMDA receptors consists of an amino terminal domain, 
a ligand binding domain, three transmembrane domains (M1, M3 and M4), a re-entrant loop 
(M2) and a carboxy terminal domain. The N-terminus is located extracellularly and the C-
terminus is at the intracellular region (Fig. 1.3).  
 
Fig. 1.3. Modular structure of a NMDA subunit. It consists of an amino terminal domain 
(ATD), a ligand binding domain (LBD), three transmembrane domains (M1, M3 and M4), a 
re-entrant loop (M2) and a carboxy terminal domain (CTD). 
 
1.3.1 The amino terminal domain (ATD) 
The ATD is composed of the first 400 amino acids located extracellularly (Fig. 1.3). 
It has a weak structure homology with the bacterial amino-acid binding protein, leucine 
isoleucine valine binding protein (LIVBP) (Masuko et al., 1999; Paoletti et al., 2000; 
Marinelli et al., 2007). The crystal structure of the monomeric NR2B ATD demonstrates that 
the ATD has a clamshell-like architecture composed of two domains (R1 and R2). These two 
domains are connected to each other by three well-structured loops (Karakas et al., 2009). The 
ATD is an important site for the modulation of the NMDA receptors (Hansen et al., 2010). 
Depending on the subunit composition, the ATD can modulate the function of NMDA 
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and redox agents (Traynelis et al., 1995; Gallagher et al., 1997; Masuko et al., 1999; 
Fayyazuddin et al., 2000; Low et al., 2000; Choi et al., 2001; Perin-Dureau et al., 2002a; 
Hatton and Paoletti, 2005; Rachline et al., 2005; Madry et al., 2007a; Han et al., 2008; Gielen 
et al., 2009; Mony et al., 2009b). The ATD is also involved in the assembly and trafficking of 
the NMDA receptors (Meddows et al., 2001; Qiu et al., 2009). The ATD of the NR2 
participates in the modulation of channel kinetics and the agonist and partial agonist potencies 
(Madry et al., 2007a; Gielen et al., 2009; Yuan et al., 2009a; Dravid et al., 2010).  
1.3.2 The ligand binding domain (LBD) 
The LBD is made up of two discontinuous segments, S1 and S2 (Stern-Bach et al., 
1994). The S1 is the region between the ATD and M1 and the S2 is the extracellular loop 
between M3 and M4 (Fig. 1.3). The LBD lies extracellularly. Similar to the ATD, the LBD 
has a clamshell-like structure and also has a weak structure homology with the LIVBP 
(Kuryatov et al., 1994; Stern-Bach et al., 1994; Furukawa and Gouaux, 2003). The LBD of 
the NR1 heterodimerizes with that of the NR2, forming an asymmetric unit. They are 
arranged in a back-to-back fashion, making various contacts, namely subsite I, subsite II and 
subsite III (Furukawa et al., 2005). The LBD is the region for agonist binding. For the NR1, 
the LBD binds to the co-agonist glycine or the endogenous D-serine in the CNS while that of 
NR2 binds to the agonist glutamate (Shleper et al., 2005). The selectivity of NR1 for glycine 
is due to Val
689
 (absence of hydroxyl group) and Trp
731
 (presence of indole ring), which 
preclude hydrogen bonding with γ-carboxylate oxygen of glutamate. Instead, the Arg523 and 
Arg
732
 form hydrogen bond with the α-carboxylate group and the carboxy group of glycine 
respectively. In particular, Arg
732
 is not present in other iGluRs (Furukawa and Gouaux, 









 in the NR2A allow binding with NMDA (Furukawa et al., 2005). Upon binding to the 
agonist glutamate and the co-agonist glycine, the closure of the LBD changes in 
conformation which eventually results in the opening of the ion channel (Kleckner and 
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Dingledine, 1988; Lerma et al., 1990). Besides modulating the ion channel states (open state, 
closed state and desensitized state) through ligand binding, the LBD is also considered to be 
the critical domain in coupling the modulating action of the ATD to the ion channel (Lester 
and Jahr, 1992; Krupp et al., 1998; Villarroel et al., 1998; Regalado et al., 2001; Zheng et al., 
2001; Chen et al., 2004b; Erreger and Traynelis, 2005; Gielen et al., 2008; Zhang et al., 
2008).  
1.3.3 The transmembrane domain 
There are three transmembrane domains, M1, M3 and M4 and a re-entrant loop M2 
(Fig. 1.3). M1-4 forms the channel pore of the NMDA receptors. The extracellular vestibule 
is formed by the M1, M3 and M4 of the NR1 subunit. The pre-M1, pre-M4 and the regions C-
terminal to M3 form the superficial part while M3 forms the core of the extracellular vestibule 
(Beck et al., 1999; Sobolevsky et al., 2002b). The M3 of the NR2 also contributes to the core 
of the extracellular vestibule but is located more externally to that of NR1, thus resulting in 
staggering pattern (Sobolevsky et al., 2002a). From the core of the extracellular vestibule, M3 
leads to the channel’s narrow constriction. Thus, M3 is important in channel gating (Jones et 
al., 2002; Sobolevsky et al., 2002b; Low et al., 2003; Hu and Zheng, 2005b; Yuan et al., 
2005; Chang and Kuo, 2008). The narrow constriction is formed by the non-homologous 
asparagines at the tip of the re-entrant loop M2. M2 makes up the cytoplasmic vestibule of the 
channel (Kuner et al., 1996; Wollmuth et al., 1996). Extracellular Mg
2+
 binds to M2 and 
binding is strongly voltage-dependent (Kupper et al., 1996; Williams et al., 1998; Wollmuth 




 will selectively 
pass through the pore via electrostatics or coordination chemistry (Dingledine et al., 1999).  
1.3.4 The carboxy terminal domain (CTD) 
The CTD is the region after the M4 domain (Fig. 1.3). It is the key region for 
interaction with a large complex of cytoplasmic proteins. These proteins include scaffolding 
proteins, adaptor proteins, cell adhesion proteins, cytoskeletal proteins and components of 
signal transduction pathways. The CTD harbors a conserved sequence ESDV (at NR2A and 
12 
 
NR2B) or ESEV (at NR2C and NR2D) which is crucial in binding to a family of proteins 
known as the membrane associated guanylate kinase (MAGUK) (Hung and Sheng, 2002; 
McGee and Bredt, 2003; Prybylowski and Wenthold, 2004). Members of MAGUKs which 
interact with the NMDA receptors include postsynaptic density-95 (PSD-95), synapse-
associated protein 97 (SAP97), PSD-93 and SAP102 (Sheng and Pak, 2000; Gardoni, 2008). 
The CTD of each NMDA receptor subunit binds uniquely to the MAGUKs (Cousins et al., 
2008; Zhang and Diamond, 2009). Attachment to the MAGUKs brings about interaction with 
a wide range of signaling molecules such as neuronal nitric oxide synthase (nNOS), protein 
kinases and various regulators of small G-proteins (Brenman et al., 1996; Husi et al., 2000; 
Hung and Sheng, 2002). This makes the CTD of the NMDA receptors subunits critical for 
modulating the downstream signaling (Kim et al., 1998; Komiyama et al., 2002; Kim et al., 
2005; Tu et al., 2010). The CTD also associates with components of cytoskeletal proteins 
such as α-actinin (a spectrin/dystrophin family of actin-binding proteins), yotiao (a 
filamentous protein) and myosin regulatory light chain (accessory light chain of the actin-
based motor myosin II) (Wyszynski et al., 1997; Lin et al., 1998; Bajaj et al., 2009). The 
interaction with the cytoskeletal components are important for the trafficking from the 
nucleus to the PSD and the organization of the NMDA receptors at the PSD (Carlisle and 
Kennedy, 2005). The CTD also harbors serine/threonine kinases and the protein tyrosine 
kinases phosphorylation sites (Fig. 1.4) (Dingledine et al., 1999; Chen and Roche, 2007).  
Phosphorylation regulates NMDA receptors’ kinetics, POPEN and conductances, thereby 
modulating NMDA receptors funtcions (Wang and Salter, 1994; Xiong et al., 1998; Liao et 
al., 2001; Krupp et al., 2002). Phosphorylation also regulates the trafficking of the NMDA 
receptors by modulating their ability to bind to other proteins (Lan et al., 2001; Vissel et al., 
2001; Grosshans et al., 2002; Chung et al., 2004; Chen and Roche, 2009; Jeffrey et al., 2009). 
The type of phosphorylation is also subunit specific (Fig. 1.4). The interaction with various 
intracellular proteins that are involved in downstream signaling and trafficking makes the 




Fig. 1.4. Schematic diagram showing the CTD of NR1 and NR2A-C and their respective 





1.4 Activation, relaxation and the endogenous modulators of the NMDA receptors 
1.4.1 Activation  
Activation of the NMDA receptors requires the binding of the agonist glutamate and 
the co-agonist glycine or the endogenous D-serine and the relief of the Mg
2+
 channel block. 
Binding of the agonists is sequential in manner, with each subunit undergoing a 
conformational change upon binding (Banke and Traynelis, 2003). The conformational 
changes are related to each other (Gibb and Colquhoun, 1991, 1992; Clements and 
Westbrook, 1994; Chen et al., 2008b). Conformational changes eventually bring about the 
opening of the channel pore, allowing the efflux of potassium (K
+





 (Benveniste and Mayer, 1991; Clements and Westbrook, 1991; Lester et al., 
1993; Nahum-Levy et al., 2001; Nahum-Levy et al., 2002). There are three possible 
consequences upon the binding of agonists; (1) an open state (ion-conducting state) of the 
receptors, (2) desensitization (long-lived non-conducting state) and (3) the unbinding of 
agonists (Lester et al., 1990; Lester and Jahr, 1992) . All three can happen with equal 
probability (Popescu et al., 2004). Considering the numerous conformational changes 
involved and the dynamics of the NMDA receptors, there are at least three open states and 
five close states observed in the NR2A-expressing NMDA receptors (Stern et al., 1994; 
Wyllie et al., 1998). The relative occupancy in the open and the close states determines three 
discrete modes of activity, i.e. high, medium and low channel POPEN (Popescu and Auerbach, 
2003). The transition among gating modes also determines the relaxation time course (Zhang 
et al., 2008). Thus within a single activation, the NMDA receptors have multiple conductance 
level, prolonged periods of intense activity and multiple shut-time components (Cull-Candy 
and Usowicz, 1987; Jahr and Stevens, 1987; Ascher et al., 1988; Gibb and Colquhoun, 1991; 
Popescu and Auerbach, 2003). Kinetics of the NMDA receptors are relatively slow compared 
to other glutamate receptors due to the requirement of multiple conformational changes 
(contributing to the slow rise time; 7-15 ms) and higher apparent affinity for glutamate 
(contributing to the slow decay time; 22-4408 ms) (Cull-Candy and Usowicz, 1987; Jahr and 
Stevens, 1987; Ascher et al., 1988; Lester et al., 1990; Chen et al., 1999; Erreger et al., 2004). 
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The slow rise time and decay time of the NMDA receptors contribute to the slow component 
of the excitatory postsynaptic potentials (EPSPs) which makes a dominant contribution to the 
temporal integration of synaptic inputs (Hestrin et al., 1990; Maccaferri and Dingledine, 
2002). Given the pivotal role of NMDA receptors in many physiological and 
pathophysiological conditions, the NMDA receptors are tightly regulated by extracellular and 
intracellular factors. Desensitization of the receptors is also crucial in preventing 
overactivation of the receptors.  
1.4.2 Relaxation  
Relaxation or the decay of the NMDA receptors has biphasic kinetics. The fast and 
slow components of decay are due to the occupancy of different close states (Zhang et al., 
2008). The close states of the receptors are the result of desensitization. There are three main 
forms of desensitization; Ca
2+
-dependent inactivation, glycine-dependent desensitization and 
glycine-independent desensitization. The composite of the different forms of inactivation and 
desensitization will determine the overall degree of current flow following activation of the 
NMDA receptors.  
1.4.2.1 Ca2+-dependent inactivation 
Ca
2+
-dependent inactivation results in a decrease in open channel probability 
following a rise in intracellular Ca
2+
 generated by Ca
2+
 entry through the NMDA receptors or 
through other routes (Vyklicky, 1993; Tong and Jahr, 1994; Rosenmund et al., 1995; Tong et 
al., 1995; Rycroft and Gibb, 2004; Wang et al., 2008). Ca
2+
-dependent inactivation is 
mediated through an interaction of the CTD with the intracellular proteins and involves the 
signaling of second messenger systems downstream (Krupp et al., 1999; Rycroft and Gibb, 
2004; Wang et al., 2008). This brings about a slower time course of desensitization compared 
to the other two forms (seconds versus tens or hundreds of milliseconds) (Mayer et al., 1989; 
Medina et al., 1995). Intracellular Ca
2+
 induces the binding of calmodulin at the CTD of NR1 
which affects the interaction of CTD with cytoskeletal proteins such as α-actinin, and this 
eventually results in the inactivation of NMDA receptors through the translocation of the 
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receptors (Ehlers et al., 1996; Zhang et al., 1998; Krupp et al., 1999; Lu et al., 2000; Rycroft 
and Gibb, 2004; Wang et al., 2008). Phosphorylation states at the CTD of the NMDA 
receptors are crucial in this form of desensitization. Calcineurin, a Ca
2+
-binding protein, and 
tyrosine phosphatase dephosphorylate the NR2A receptors, thereby increasing the Ca
2+
-
dependent inactivation while phosphorylation by kinases such as protein kinase A (PKA) and 
PKC has the opposite effect (Klee et al., 1979; Tong et al., 1995; Westphal et al., 1999; Lu et 
al., 2000; Krupp et al., 2002; Jackson et al., 2006). The extent of desensitization is NR2 
subunit-dependent since NR2A, but not NR2C receptors, is sensitive to Ca
2+
-dependent 
inactivation (Krupp et al., 1996; Vissel et al., 2002). Ca
2+
/calmodulin-dependent protein 
kinase II (CaMKIIα) also enhances the NR2B desensitization through phosphorylation at the 
Ser
1303
 and this is dependent on intracellular Ca
2+
 (Sessoms-Sikes et al., 2005).  
1.4.2.2 Glycine-dependent desensitization 
This refers to the decrement of NMDA receptor currents when the glycine 
concentration is not saturating and this form of desensitization can be overcome by increasing 
the concentration of glycine to saturation level (Benveniste et al., 1990; Lerma et al., 1990; 
Vyklicky et al., 1990). As glycine is a required co-agonist, subsaturating concentration of 
glycine gives a perceived desensitization of the receptors. It is observed that upon glutamate 
binding, the apparent affinity of glycine decreases due to negative allosteric coupling between 
the glutamate binding site at the NR2 and the glycine site at the NR1 subunit (Mayer et al., 
1989; Lester et al., 1993). Similarly, NMDA receptors desensitize in an agonist-dependent 
manner when the glutamate concentration is subsaturating (Nahum-Levy et al., 2001; Nahum-
Levy et al., 2002). As the affinity for glycine is subunit dependent, the glycine-dependent 
desensitization is also subunit-dependent (Kendrick et al., 1998). Modulators affecting the 
apparent affinity of glycine also influence the glycine-dependent desensitization. Polyamine 
increases the rate of glycine-dependent desensitization probably through the increase in the 
apparent affinity for glycine and a decrease in the rate of dissociation for glycine (Benveniste 
and Mayer, 1993).  
17 
 
1.4.2.3 Glycine-independent desensitization 
This refers to the desensitization of the NMDA receptors when the glycine 
concentration is in saturation and it is independent of Ca
2+
 concentration. The domains 
involved in this form of desensitization are observed to reside at the pre-M1 domain and the 
ATD domain (Krupp et al., 1998; Villarroel et al., 1998). NR2A- and NR2B-expressing 
receptors. Zn
2+
 accelerates the macroscopic desensitization of NR1/NR2A and NR1/NR2B 
receptors in a dose-dependent manner (Chen et al., 1997). The mechanism behind the Zn
2+
-
dependent desensitization is the allosteric modulation between the ATD and glutamate 
binding site. Upon binding to glutamate, the apparent affinity for Zn
2+
 increases. This shifts 
the relaxation of the macroscopic current to a new equilibrium. Higher degree of 
desensitization is observed with higher concentration of glutamate. Similar interaction 
between the ifenprodil binding site and glutamate binding site is observed in NR1/NR2B 
receptors (Zheng et al., 2001). Similarly, it is also observed that in the presence of Zn
2+
, the 
half maximal effective concentration (EC50) of glutamate decreases, probably due to the 
decrease in glutamate affinity (Erreger and Traynelis, 2005). Zn
2+
-dependent desensitization 
is subunit-dependent, i.e. NR2A and NR2B are significantly desensitized but not NR2C since 
Zn
2+
 binds with different affinity to these receptors (Chen et al., 1997; Paoletti et al., 1997; 
Kendrick et al., 1998). However, this is in contrast with results from Hu and Zheng (2005) 
where they observed glycine-independent desensitization is not dependent on the above 
mentioned sites but on the residues in the lurcher motif of NR1 or NR2A (Hu and Zheng, 
2005a). The highly conserved lurcher motif located at the M3 is important for channel gating 
(Kohda et al., 2000; Taverna et al., 2000; Jones et al., 2002). Mutants in the lurcher motif 
cause a reduction in glycine-independent desensitization and a slower deactivation time 
constants (Kohda et al., 2000; Hu and Zheng, 2005b). Other pore mutants such as Met
823
 in 
the M4 domain of NR2A and Asn
598
 in the M2 of NR1 also affect the desensitization and 
channel gating (Ren et al., 2003; Chen et al., 2004a). Thus the change in desensitization may 
be accounted for by a change in gating rate. There is also a type of desensitization that is 




 but related to the interaction with PSD-95. The 
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interaction with PSD-95 modulates the localization of the NMDA receptors and is important 
in modulating the desensitization changes during development (Li et al., 2003; Sornarajah et 
al., 2008).  
1.4.3 Endogenous modulators 
In view of their involvement in various physiological and pathophysiological 
conditions, the NMDA receptors are tightly regulated by desensitization and extracellular 






, polyamine and a redox environment. NMDA receptors are 
also regulated intracellularly. Such modulators include kinases, phosphatases and scaffolding 
proteins. Phosphorylation can alter the channel properties. It can also modulate the interaction 
between the NMDA receptors with scaffolding proteins thereby regulating the localization of 
NMDA receptors (van Zundert et al., 2004; Gardoni and Di Luca, 2006; MacDonald et al., 
2006; Groc et al., 2009).  
1.4.3.1 Modulation by H+ 
An increase in the exttracellular concentration of H
+
 can suppress the NMDA-
activated current. H
+
 is a non-competitive ligand as it does not affect the affinities of the 
agonists (Tang et al., 1990). Inhibition by H
+
 has no effect on the unitary conductance or 
individual open dwell times. Rather, H
+
 inhibition is voltage-insensitive and decreases the 
opening frequency of NMDA receptors, thereby reducing the POPEN, without altering the time 
course of desensitization or deactivation (Traynelis and Cull-Candy, 1990; Banke et al., 
2005). It is NR1 splice variant-specific with splice variants containing the positively charged 
residues at the C-terminus end of exon 5, shielded from the tonic H
+
 inhibition (Traynelis et 
al., 1995). It is also dependent on the NR2 subunit with NR2C as the least and NR2B and 
NR2D as the most sensitive to H
+
. IC50 of H
+
 for NR2B and NR2D is ~pH 7.4, indicating that 
under normal condition, half of the NMDA receptors will be under tonic inhibition (Traynelis 
et al., 1995; Low et al., 2003). The physical binding sites to H
+
 are dispersed in several 
regions, including the linker between M3 and S2 of the NR1 and the linker between S2 and 





 (Gielen et al., 2009). Proton inhibition is tightly coupled to the movement of 
the gating pore (Kashiwagi et al., 1997; Traynelis et al., 1998; Jones et al., 2002; Sobolevsky 
et al., 2002a; Low et al., 2003; Banke et al., 2005). Modulation of H
+
 sensitivity appears to be 
a common downstream mechanism for a number of the NMDA receptors’ allosteric 
modulators (see below). Thus H
+
 acts as an intrinsic protective mechanism when the H
+
 
concentration is high during hypoxic/ischemic conditions (Giffard et al., 1990; Kaku et al., 
1993).  
1.4.3.2 Modulation by Mg2+ 
Mg
2+
 ion binds at a site located at the channel pore of the NMDA receptors thus Mg
2+
 
binding effectively blocks the conductance of the NMDA receptors (Kuner et al., 1996; 
Williams et al., 1998; Yuan et al., 2005). As there is an electric field due to the membrane 
potential across the plasma membrane, the association and dissociation of Mg
2+
 is sensitive to 
changes in the membrane potential (Ascher and Nowak, 1988; Jahr and Stevens, 1990; 
Premkumar and Auerbach, 1996; Vargas-Caballero and Robinson, 2004). Negative 
membrane potential favors Mg
2+
 binding and thus Mg
2+
 dissociates from its binding site upon 
membrane depolarization (Wollmuth et al., 1998; Vargas-Caballero and Robinson, 2004). 
The Mg
2+
 block of the NMDA receptors is therefore voltage-dependent. Upon depolarization, 
Mg
2+
 can be driven through the channel pore making it a permeant channel blocker (Mayer 
and Westbrook, 1987; Ascher and Nowak, 1988; Wollmuth et al., 1998). There are two 
components of Mg
2+
 unblock; a slow component (of several milliseconds) and a fast 
component (of less than 1 ms) (Spruston et al., 1995; Vargas-Caballero and Robinson, 2003; 
Kampa et al., 2004; Vargas-Caballero and Robinson, 2004; Clarke and Johnson, 2006). The 
slow unblock is dependent on NR2, resulting in different sensitivity to Mg
2+
 blockade 
(Monyer et al., 1992; Ishii et al., 1993; Monyer et al., 1994; Clarke and Johnson, 2006). 
However, NR3A and NR3B are insensitive to Mg
2+
 block (Chatterton et al., 2002).  
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1.4.3.3 Modulation by Zn2+ 
Zn
2+
 inhibits the peak glutamate-evoked current responses in a non-competitive 
manner (Chen et al., 1997; Fayyazuddin et al., 2000; Rachline et al., 2005). Zn
2+
 inhibits by 
binding to two sites, namely (1) a high affinity, voltage-independent site and (2) a low 
affinity, voltage-dependent site (Williams, 1996; Chen et al., 1997; Paoletti et al., 1997; 
Traynelis et al., 1998). The high affinity Zn
2+
 inhibition is attributable to the slow dissociation 
of Zn
2+
 from its binding site (Paoletti et al., 1997). Using electrophysiological techniques and 
analysis based on the crystal structure of ATD, Zn
2+
 is characterized to bind to the cleft of the 
ATD to mediate the high affinity inhibition (Choi and Lipton, 1999; Fayyazuddin et al., 2000; 
Low et al., 2000; Paoletti et al., 2000; Karakas et al., 2009).  However, binding affinity differs 
among the NR2 subunits with the IC50 spanning more than three orders of magnitude: from 
low nM for NR2A receptors, to 1 µM for NR2B receptors and ≥ 10 µM for NR2C and NR2D 
receptors (Chen et al., 1997; Paoletti et al., 1997; Traynelis et al., 1998; Rachline et al., 2005). 
The high affinity of Zn
2+





 in NR2A which are not conserved in the NR2 subunits (Chen et al., 1997; Choi and 
Lipton, 1999; Low et al., 2000). Although Zn
2+
 binds with high affinity to the ATD of NR2A, 
the voltage-independent inhibition on NR2A is incomplete. However, the incomplete Zn
2+
 
inhibition is not observed in the other NR2 subunits (Rachline et al., 2005). The partial 
incomplete inhibition by Zn
2+





inhibition is enhanced in the presence of H
+
. The saturating Zn
2+
 cannot completely inhibit 
due to non-saturating H
+
 concentration under physiological condition (Traynelis et al., 1998; 
Low et al., 2000). Factors affecting the H
+
-inhibition, like the exon 5 of NR1 splice variant, 
would thus, affect the voltage-independent Zn
2+





 inhibition is also allosterically regulated by other modulators or 
ligands. Glutamate binding on the LBD of NR2 has a positive allosteric modulation on Zn
2+
 
binding to the ATD of NR2A. This also mediates the fast desensitization of NR2A-expressing 
NMDA receptors (Zheng et al., 2001). Channel inhibition by Zn
2+
 through the ATD is a 
demonstration of the transduction of signal from the ATD to the LBD by conformational 
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movement (Gielen et al., 2008). Although the binding site for Zn
2+
 is at the ATD, tyrosine 
kinase phosphorylation at the CTD can also modulate the Zn
2+
 inhibition at the ATD (Zheng 
et al., 1998). For the low affinity, voltage-dependent Zn
2+
-inhibition, it involves the binding 
of Zn
2+
 to a region near the channel pore (Christine and Choi, 1990). Unlike the voltage-
independent Zn
2+
 inhibition, the voltage-dependent Zn
2+
-inhibition shows no subunit 
specificity (Paoletti et al., 1997). The voltage-dependent block may work in a similar way as 
the Mg
2+
 channel block. However, Zn
2+
 can permeate more easily than Mg
2+
, thus the voltage 
dependent block of Zn
2+
 is lower than that of Mg
2+
 (Legendre and Westbrook, 1990; Paoletti 
et al., 1997). Indeed, the inhibition by Zn
2+
 is observed to protect neurons from excitotoxic 
insults that are induced by glutamate or NMDA (Choi and Koh, 1998; Cote et al., 2005). 
Despite the understanding on the inhibition by Zn
2+
, it is still controversial whether Zn
2+
 
inhibits NMDA receptors in a tonic or phasic manner (Vogt et al., 2000; Kay, 2003; Izumi et 
al., 2006; Kay, 2006). More studies have to be carried out to understand how Zn
2+
 regulates 
the NMDA receptors in the CNS.  
1.4.3.4 Modulation by polyamine 
Polyamines are polybasic aliphatic amines that are positively charged at physiological 
pH. The endogenous polyamines are synthesized from ornithine, a byproduct of the urea 
cycle. In the CNS, they are released by neurons and/or glial cells (Masuko et al., 2003). 
Polyamine produces three different effects on the NMDA receptors, (1) a voltage-dependent 
block, (2) a glycine-dependent potentiation and (3) a voltage- and glycine-independent 
potentiation (Rock and Macdonald, 1995; Williams, 1997b; Mony et al., 2009a). These 
effects are not observed in NR2C and NR2D (Williams, 1995). High concentration of 
polyamine promotes the voltage-dependent block of the NMDA receptors with the block 
being more pronounced at hyperpolarized potentials. Block by polyamine is mediated by the 
interaction with residues from the M3 of NR1 and NR2B, the S2 of NR1 and the linker 
between M1 and M2 of NR2 (Kashiwagi et al., 1996; Kashiwagi et al., 1997; Jin et al., 2008). 
Polyamine binding at the opening of the pore impedes ion flow and causes a decrease in the 
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unitary conductance and the average open duration that is distinct from the voltage-dependent 
Mg
2+
 block (Brackley et al., 1990; Rock and Macdonald, 1992a, b; Williams, 1997a). 
Inhibitory effects are similar in both NR2A and NR2B (Williams, 1994; Sharma and 
Reynolds, 1999). However, low concentration of polyamine results in the stimulation of the 
NMDA receptors (Brackley et al., 1990; Rock and Macdonald, 1992a; Mony et al., 2009a).  
Polyamine increases the NMDA receptors’ affinity for glycine (McGurk et al., 1990; Ransom 
and Deschenes, 1990). Increase in the affinity of glycine decreases the rate of development of 
glycine-dependent desensitization and the rate of dissociation of glycine from the NMDA 
receptors. However, the rate for dissociation of NMDA is not reduced (Benveniste and 
Mayer, 1993). This results in the glycine-dependent stimulation by polyamine. This form of 
stimulation is observed in both NR2A- and NR2B-expressing receptors (Williams, 1994). 
Voltage- and glycine-independent stimulation is unique to NR2B subunits (Williams, 1994; 
Sharma and Reynolds, 1999). This form of stimulation causes an increase in the channel 
opening frequency but no change in average open time or amplitude. Polyamine can also 
potentiate the steady-state current (i.e. the desensitized response) in a dose-dependent manner. 
The desensitization onset rate is affected by polyamine (Lerma, 1992; Rumbaugh et al., 
2000). Polyamine binds to the ATD of NR1 and NR2B (Williams, 1995; Masuko et al., 1999; 
Han et al., 2008). Site of binding on NR2B is distinct from that of ifenprodil, a NR2B-specific 
drug (Gallagher et al., 1996; Kew and Kemp, 1998; Han et al., 2008). It is also observed that 
polyamine stimulation involves the interplay with proton through a relief in proton inhibition 
(Williams et al., 1995; Kashiwagi et al., 1996). Polyamine, being positively charged, acts like 
the exon 5 insert of the NR1 splice variants, relieving H
+
 inhibition. Thus, polyamine 
stimulation is not effective on NR1-(1-4)b splice variants as proton inhibition is relieved by 
the positive residues contributed by the exon 5 insert (Durand et al., 1993; Traynelis et al., 
1995). Even when NR1-(1-4)b/NR2B is co-expressed, this form of stimulation does not occur 
(Durand et al., 1993; Williams, 1994; Zheng et al., 1994). In view of the various effects of 
polyamine acting on the different subtypes of NMDA receptors, the effects of polyamine vary 
widely between individual neurons due to the different NMDA receptors expressed on 
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different neurons (Williams et al., 1990; Lerma, 1992; Rock and Macdonald, 1992a, b; 
Benveniste and Mayer, 1993; Araneda et al., 1999).  
1.4.3.5 Modulation by redox activity and S-nitrosylation 
Certain cysteine residues are observed to be sites for redox modulation. Cysteine 
contains a thiol side chain which is able to form disulfide bond with neighboring cysteines 
during oxidized condition or remains as thiols in reduced condition. Several pairs of disulfide 
bonds are observed in the ATD and the LBD crystal structure (Table 1.1) (Furukawa and 
Gouaux, 2003; Karakas et al., 2009). Three of the disulfide bonds are redox modulation sites 
with two of them from the ATD and one of them located at the LBD (Table 1.1) (Choi et al., 
2001). Upon reduction of these disulfide bonds by the reducing agent dithiothreitol (DTT), 
NMDA receptors are potentiated whereas oxidation by 5-5-dithiobis-2-nitrobenzoic acid 
(DTNB) decreases the magnitude of response (Aizenman et al., 1989; Tang and Aizenman, 
1993). Reduction of the disulfide bond increases the open dwell time and open frequency of 
NR1/NR2A receptors but only increases the open frequency of NR1/NR2B and NR1/NR2C 
receptors (Brimecombe et al., 1997; Brimecombe et al., 1999). Upon DTT reduction, 









 of NR1 
underlies the intermediate component. These two components are only observed in 




 of NR2B 
are homologous to these residues and are observed to form disulfide bond based on the 










 of NR1 mediate the persistent component that are observed in all NR2 
subunits when expressed with NR1 (Kohr et al., 1994; Sullivan et al., 1994; Brimecombe et 
al., 1999; Choi et al., 2001). Although these cysteines are not physically involved in the 




, their redox status are crucial for their 
modulation on the NMDA receptors (Tang and Aizenman, 1993; Sullivan et al., 1994; Gozlan 
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and Ben-Ari, 1995; Choi et al., 2001; Kaye et al., 2007; Karakas et al., 2009). This could 
indicate that the disulfide bridges formed between these cysteines are important in 
maintaining structural configuration of the receptors and the reduction in the disulfide bond 
leads to conformational changes that affect the sensitivity of the receptors to such modulators. 
The free thiol groups of cysteines can also form S-nitrosothiol in the presence of 
nitric oxide (NO) (Ignarro, 1990). NO interacts and S-nitrosylates predominantly the Cys
399
 of 
NR2A, decreasing the number of channel openings and resulting in a down regulation of 
evoked current. This acts as an important neuroprotection during NMDA-induced 
excitotoxicity (Lei et al., 1992; Lipton et al., 1993; Kim et al., 1999; Lipton et al., 2002). 
Cys
399
, which is not conserved among the NR2 subunits, lies in the linker region. The linker 
region is important for determining the differential channel kinetics of NR2-expressing 
NMDA receptors (Gielen et al., 2008; Yuan et al., 2009a). This may explain the uniqueness 
of NR2A compared to other NR2 subunits. The other three pairs of cysteines involved in 
redox action can only be S-nitrosylated when they are in the free thiol forms (i.e. their 
reduced state) (Table 1.1) (Aizenman and Potthoff, 1999; Kim et al., 1999; Choi et al., 2000).  
In view of the above, cysteines act as important redox switches and respond to the 





 of NR1 is required for light stimulation (Leszkiewicz et al., 2000; 
Leszkiewicz and Aizenman, 2002). Under pathological circumstances such as stroke, when 
the level of oxygen is low and reducing condition is favored, free thiol forms would likely be 
predominant (Yager et al., 1991; Anderson et al., 1999; Chen and Shi, 2008). As such, 




 of NR1. The disulfide bond is 
susceptible to reduction and may induce other critical sites such as Cys
399
 or itself to be more 
readily nitrosylated by NO and eventually leads to neuroprotection via nitrosylation of the 
NMDA receptors (Takahashi et al., 2007). Redox modulatory sites are also involved in 
modulating pain transmission and epileptic activity (Quesada et al., 1996; Laughlin et al., 




















 important modulators during hypoxic condition like stroke.  
 
Table 1.1. Crucial cysteines in the NMDA receptor subunits. These cysteines are located 
in different domains of the NMDA receptor subunits. From the available crystal structure and 
electrophysiological experiments, they, with exception to Cys
399
, are observed to form 
disulfide bonds and are involved in redox action and/or S-nitrosylation. Cyan and gray 
indicate the respective homologous residues.  indicates involvement and  indicates S-
nitrosylation only when in free thiol forms.  
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1.5 NMDA receptors and excitotoxicity in stroke 
Although the NMDA receptors are tightly regulated by various endogenous 
modulators, overactivation often leads to excitotoxicity. Overactivation occurs in disease 
states such as stroke. Stroke is the rapidly developing loss of brain functions due to a 
disturbance in the blood supply to the brain, usually caused by bleeding or blocked blood 
vessels. It is broadly categorized into two types based on their causes. Hemorrhagic stroke is 
caused by the rupture of blood vessels, resulting in bleeding in the brain. Ischemic stroke is 
caused by local thrombosis or embolism, resulting in a transient or permanent reduction in 
blood flow (Donnan et al., 2008). This results in a lack of glucose and oxygen supply, 
disrupting the homeostasis and the ionic gradients in the brain. The loss of membrane 
potential causes the neurons and glia to depolarize, releasing neurotransmitters into the 
synaptic cleft (Dirnagl et al., 1999; Besancon et al., 2008). Glutamate, one of the 
neurotransmitters that is released, becomes accumulated in the synaptic cleft. This results in 







 is responsible for the early necrotic events. Ca
2+
 entry results in the delayed 
neurodegenerative injuries through the activation of cytoplasmic and nuclear events (Fig. 1.5) 
(Dirnagl et al., 1999; Szydlowska and Tymianski, 2010). At the centre of the perfusion 
deficit, cells are killed rapidly. However, between the infarct core and the unaffected brain 
tissue is the penumbra. This is an area of constrained blood flow and partially preserved 
energy metabolism. Without treatment, this area proceeds to infarction due to ongoing 
excitotoxicity (Baron, 2001; Markus et al., 2004). Thus this area is a prime area for 
neuroprotection (De Silva et al., 2010). Many drugs targeting the NMDA receptors are 
developed to salvage the penumbra and prevent the spread of cell death. There are several 
regulatory sites of the NMDA receptors that are targeted; (1) the glutamate binding site, (2) 
the glycine binding site, (3) the site within the channel lumen where Mg
2+
 and phencyclidines 
bind and (4) the ATD.  However, many of these drugs are not successful in clinical trials 




Fig. 1.5. An overview of pathophysiological mechanisms in ischemic stroke. Glu indicates 
glutamate. NO indicates nitric oxide. The lack of oxygen and glucose disturb the homeostasis 
which eventually lead to the excessive release of glutamate. Overactivation of glutamate 




 postsynaptically, causing membrane 
depolarization, cell swelling, enzyme induction and mitochondrial damage. These processes 
eventually lead to cell death. (Adapted from Trends in Neurosciences 1999, 22: 391-397) 
 
1.5.1 Competitive antagonists 
Antagonists targeting the agonist or the co-agonist binding sites are likely drug 
candidates (Fig. 1.6). However, competitive antagonists discriminate poorly between the 
NMDA subtypes and result in the generalized inhibition of NMDA receptors (Paoletti and 
Neyton, 2007).  Classical competitive antagonists on the glutamate binding site are the 
phosphono derivatives of short-chain (five to seven carbons) amino acids such as D-2-amino-
5-phosphonopentanoic acid (AP5) and D-2-amino-7-phosphonoheptanoic acid (AP7) 
(Dingledine et al., 1999). Selfotel is one such drug targeting the glutamate binding site. 
However, it is terminated in phase III stroke clinical trial due to an increase in mortality, 
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possibly due to neurotoxicity (Davis et al., 1997; Davis et al., 2000). Quinoxaline-2,3-dione 
(e.g. trisubstituted 5-nitro-6,7-dichloro-qinoxaline-2,3-dione (ACEA-1021)), quinolin-2(1H)-
ones, benzazepine (e.g. 3-hydroxy-1h-1-benzazepine-2,5-diones (HBAD)), kynurenic acid 
(e.g. 7-chlorokynurenic acid (7CKA)) and substituted indole-2-carboxylates derivatives target 
the glycine binding site (Swartz et al., 1992; Kulagowski et al., 1994; Keana et al., 1995; 
Woodward et al., 1995; Di Fabio et al., 1997; Dingledine et al., 1999). Of which, gavestinel, 
an indole-2-carboxylate, is developed and tested in clinical trials. Gavestinel does not 
improve the outcome of stroke (Lees et al., 2000; Haley et al., 2005; Warach et al., 2006). As 
glycine binding is dependent on the NR2 subunit, some of the glycine site competitive 
antagonists are more potent in certain types of NR2 subtypes. For example, the dichloro-
tetrahydroquinoline-2-carboxylic acid derivative (CGP 61594) is more effective for 
NR1/NR2B receptors (Honer et al., 1998).  
1.5.2 Channel blockers 
Channel blockers have similar binding site as Mg
2+
 and are usually uncompetitive 
antagonists (Fig. 1.6). They bind to the NMDA receptors only during transmitter-activated 
state and exhibit a use-dependent and a voltage-dependent blockade. Examples of such 
channel blockers are ketamine, phencyclidine, memantine and 5-methy-10,11-dihydro-5H-
dibenzocyclohepten-5,10-imine maleate (MK-801) (Wong et al., 1986; Huettner and Bean, 
1988; Yuan et al., 2005; Johnson and Kotermanski, 2006). Binding of open channel blockers 
results in the dissociation of the agonists and the subsequent closing of the NMDA receptor 
channel. Dissociation of the channel blocker is generally slow and is dependent on the 
channel blocker binding site in the pore. The deeper it binds in the channel pore, the longer it 
will be trapped. As a result, phencyclidine and MK-801, which are suggested to bind deep 
within the channel pore, are not successful as drug candidates owing to their neuropsychiatric 
and pathological side effects (Lipton, 1993; Dravid et al., 2007). In contrast, memantine 
which has partial trapping in closed channel, is thus the only NMDA receptor antagonist 
approved as a drug (in Alzheimer’s disease) by the Food and Drug Administration (FDA) 
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(Blanpied et al., 1997; Winblad and Poritis, 1999; Reisberg et al., 2003; Tariot et al., 2004). 
Memantine also provides positive outcome in animal stroke model, but it is ineffective in the 
treatment of stroke in human trials (Chen et al., 1992; Chen et al., 1998; Lipton, 2006). 
Rather, memantine has beneficial effects for recovery from stroke (Orgogozo et al., 2002). 
Moreover, other channel blockers such as Aptiganel, Remacemide and AR-R15896AR are 
ineffective in stroke clinical trials either due to a lack of positive stroke outcome or the 
occurrence of high mortality rates (Cregan et al., 1997; Dyker and Lees, 1999; Albers et al., 
2001; Lees et al., 2001; Diener et al., 2002). Novel alternatives such as the N-alkylglycine 
and the amino-alkylcyclohexanes derivatives are thus explored (Planells-Cases et al., 2002; 
Gilling et al., 2007).   
1.5.3 Non-competitive antagonists  
These are ligands that block NMDA receptors in voltage-independent manner without 
causing significant reduction in agonist potency. One such group of drugs is the 
phenylethanolamine. A typical phenylethanolamine is ifenprodil. Ifenprodil is highly subunit 
specific, binding to only the NR2B-expressing receptors. Ifenprodil has two binding sites. The 
low affinity, voltage-dependent site is at the ion channel pore. The high affinity, voltage-
independent binding site is located at the hydrophobic pocket in the cleft of the NR2B ATD 
(Fig. 1.6) (Williams, 1993; Perin-Dureau et al., 2002a; Karakas et al., 2009). Ifenprodil 
stabilizes an agonist-bound state that has a low POPEN (Kew et al., 1996; Fischer et al., 1997). It 
has allosteric effects on the polyamine on NMDA receptors but more importantly is the 
allosteric effects on H
+
 (Kew and Kemp, 1998). Ifenprodil binding also causes a larger fraction 
of the receptors to be protonated at physiological pH and the potency of ifenprodil increases at 
low pH (Mott et al., 1998; Williams, 2001). Considering that NR2B-expressing receptors are 
involved in mediating excitotoxicity, ifenprodil represents a good drug lead (Chen et al., 
2008a; Liu and Chen, 2008). Second generation of ifenprodil analogues, such as eliprodil and 
traxoprodil (CP101606 and RO25,6981 respectively), which have greater selectivity for NR2B 
are developed. However, they fail in stroke clinical trials due to side effects or a lack of 
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efficacy (Nikam and Meltzer, 2002; Gogas, 2006). Besides phenylethanolamine-like drugs, 
non-phenylethanolamine-like analogues are also selective for NR2B receptors and act as non-
competitive antagonists. A few of such drugs that have emerged are hydroxyl-benzimidazoles, 
benzamidine, dihydroimidaoline, 4-aminoquinolines and 2- and 4- aminopyridine (Pinard et 
al., 2002; Alanine et al., 2003; Buttelmann et al., 2003; Claiborne et al., 2003; McCauley et al., 
2004). However for most of them, the site of action is largely unknown but possibly resides at 
the ATD due to some structural similarities with the phenylethanolamine (Layton et al., 2006; 
Wee et al., 2010).  
 
Fig. 1.6. Diagram showing the different domains of the NMDA receptors which the 
antagonists target to. Cyan indicates drugs that have undergone clinical trials but have 
failed. Yellow indicates the only NMDA receptor-targeting drug that is approved for use in 
Alzheimer’s disease by FDA.  
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1.6 Thrombin  
1.6.1 In coagulation cascade 
To date, tissue plasminogen activator (tPA) is the only FDA approved drug for 
treating ischemic stroke. It has a therapeutic window of three hours (h) and works by the 
activation of plasminogen to plasmin (Disorders and Stroke rt-PA Stroke Study Group, 1995). 
Plasmin is responsible for dissolution of the clot. Unlike plasmin, thrombin is involved in 
forming the clot through the conversion of soluble fibrinogen to insoluble fibrin (Mosesson, 
2005). tPA, plasmin and thrombin are serine proteases involved in the coagulation cascade, 
which determines the blood hemostasis. Upon vascular damage, tissue factor (TF), a 
transmembrane protein, becomes exposed to factor VII (FVII). The activated FVII (FVIIa) 
complexes with TF forming TF-FVIIa, triggers the coagulation cascade and results in the 
formation of the prothrombinase complex (FVa, FXa, Ca
2+
 and anionic phospholipid). FXa 
cleaves prothrombin after Arg
320
 and generates meizothrombin. This is cleaved again after 
Arg
271
 to liberate active thrombin (35.5 kDa) (Nesheim et al., 1979; Krishnaswamy et al., 
1987; Brufatto and Nesheim, 2003; Davie and Kulman, 2006). In addition to its involvement 
in forming the fibrin clot, thrombin also cleaves and activates G-protein coupled protease-
activated receptors (PAR)-1, -3 and -4 to promote platelet activation and mediate 
inflammatory responses (Ossovskaya and Bunnett, 2004; Steinhoff et al., 2005; Martorell et 
al., 2008). 
1.6.2  Structure and action of thrombin 
Thrombin has a light chain linked by a single disulfide bond to a heavy chain which, 
itself, contains three intrachain disulfide bonds (Fig. 1.7). Upon prolonged standing in 














 (Fig. 1.7) (Boissel et al., 1984). Catalytic activities 
measured by chromogenic substrates are roughly similar among thebse three species but β- 
and γ-thrombin are less active towards physiologic macromolecules such as fibrinogen 
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) is conserved among serine proteases and is important 
for the charge relay system (Kraut, 1977; Davie and Kulman, 2006). Thrombin cleaves at the 
scissile bond (P1-P1’) following basic residues. (For subsequent discussion, the terms P4, P3, 
P2, P1, P1’, P2’ and P3’ will describe the substrate peptide amino acid positions relative to 
the P1–P1’ bond and S4, S3, S2, S1, S1’, S2’ and S3’ correspond to that on the thrombin.) 
The Asp
199
 lies at the bottom of the primary specificity pocket and interacts with the basic 
residues in the P1 of the substrates (Davie and Kulman, 2006). Thrombin specificity extends 
beyond P1 and the kinetic behavior for cleavage is largely contributed by the side chain of the 
surrounding amino acids of P1 on the substrates (Table 1.2) (Lottenberg et al., 1983; Le 
Bonniec et al., 1991; Le Bonniec et al., 1996; Backes et al., 2000; Marque et al., 2000; 
Petrassi et al., 2005). The restricted specificity compared to trypsin (a typical serine protease) 
is due to the presence of two protruding loops, a 60 loop and a γ-loop, which partially occlude 
the substrate binding cleft of thrombin. The 60 loop usually makes contacts with hydrophobic 
residues at the amino terminal end of scissile bond while the γ-loop determines specificity of 
residues at the carboxy terminal end of the scissile bond (Bode et al., 1989; Dang et al., 1997; 
Davie and Kulman, 2006). There are two other surface regions, exosite I and II, located at 
opposite ends of the substrate binding groove at the heavy catalytic chain, which confer the 
exceptional specificity of thrombin towards macromolecular substrates (Davie and Kulman, 
2006). The exosite I and exosite II interact with negatively charged groups of thrombin 
substrates. Exosite I, also known as the fibrinogen-binding exosite, exists only in α-thrombin 
as this region is cleaved off in β- and γ-forms (Tsiang et al., 1995; Pechik et al., 2004). 





Fig. 1.7. Autolysis of thrombin. Cleavage sites are indicated by arrows. Light chain is linked 
to the heavy chain through a disulfide bond. Disulfide bonds on the heavy chain are indicated 
by . The catalytic triad is highlighted in cyan. The fragments of β-thrombin and γ-
thrombin are held together by noncovalent forces. Some polypeptide are lost in the process, 
which causes different binding capabilities among the α-, β-, and γ- thrombin.  
 
 
Table 1.2. Preferred amino acids for thrombin cleavage. The terms P4, P3, P2, P1, P1’, 
P2’ and P3’ describe the substrate peptide amino acid positions relative to the P1-P1’ bond. 
Thrombin cleaves at the bond between P1 and P1’. Amino acids are represented by their 
three-letters amino acid code. X indicates the site can be any amino acids.  
 
1.6.3 Localization and regulation in the brain 
In addition to the prothrombin that is released from the liver into the blood stream, 
prothrombin mRNA is also expressed in neuronal and glial cells (Niclou et al., 1994; Arai et 
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al., 2006). Prothrombin is distributed in the olfactory bulb, cortex, colliculus superior and 
inferior, corpus striatum, thalamus and hippocampus of the brain (Dihanich et al., 1991). The 
prothrombin activator, FX, is also expressed in the brain (Shikamoto and Morita, 1999). It is 
likely that the action of thrombin in the CNS becomes more prominent under pathological 
condition when the blood brain barrier is disrupted and thrombin-activating factors, 
prothrombin and thrombin extravasate into the brain parenchyma (Sinnreich et al., 2004; 
Sokolova and Reiser, 2008). In support of this, levels of prothrombin and thrombin are 
observed to be augmented in patients with neurodegenerative disorders, such as Parkinson’s 
disease (PD), human immunodeficiency virus encephalitis, Alzheimer’s disease (AD), 
ischemic and hemorrhagic stroke (Riek-Burchardt et al., 2002; Boven et al., 2003; 
Karabiyikoglu et al., 2004; de Castro Ribeiro et al., 2006; Grammas et al., 2006; Ishida et al., 
2006; Cuomo et al., 2007; Hua et al., 2007).  
Under physiological condition, thrombin is regulated by the serine protease inhibitor 
(serpin) superfamily (Pike et al., 2005). In the brain, antithrombin III (ATIII) and protease 
nexin I (PN-1) are serpins that are expressed in neurons and various glial cell subtypes at 
different developmental stages (Choi et al., 1990; Deschepper et al., 1991; Mulligan et al., 
1991; Mansuy et al., 1993; Smirnova et al., 1996; Kury et al., 1997; Niclou et al., 1998; 
Docagne et al., 1999). However, during pathological condition, their levels do not increase 
with the rise in thrombin activity (Vaughan et al., 1994; Riek-Burchardt et al., 2002). This 
results in a less efficient inhibitory system by the serpins in modulating the increasing levels 
of thrombin during pathological condition.  
1.6.4 Function in brain 
Many of the thrombin actions in the brain are mediated via PARs, which are ubiquitous 
in the brain (Junge et al., 2004). Thrombin acts as a mitogen in cultured microglia and 
astrocytes and also as a neuroinflammatory agent through the activation of PARs (Moller et 
al., 2000; Meli et al., 2001; Suo et al., 2002; Wang et al., 2002a; Wang et al., 2002b; Nicole et 
al., 2005; Wang et al., 2007). Thrombin is found to play a role in the disease development of 
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PD, AD and stroke patients. For example, thrombin mediates the loss of striatal neurons in the 
striatum and dopaminergic neuron in the substantia nigra through activation of cFos and 
extracellular signal-regulated kinase (Erk1/2) pathway via by PAR-4 while thrombin may also 
induce neuroprotection via activation of PAR-1 in PD rat models (Cannon et al., 2005; Lee et 
al., 2005; Cannon et al., 2006; Herrera et al., 2008). Not only so, thrombin also takes part in 
the formation of amyloid plaques, characteristic of AD patients. Thrombin is involved in the 
release and the processing of amyloid precursor protein (APP) to beta amyloid in amyloid 
plaques (Igarashi et al., 1992; Li et al., 1998b). In addition, it is also observed that thrombin 
can result in neuronal death, glial scarring and cognitive deficits. On the other hand, it is 
notable that thrombin is able to promote neuronal cell survival in AD animal models 
(Akiyama et al., 1992; Russo et al., 2002; Mhatre et al., 2004; Arai et al., 2006; Luo and 
Grammas, 2010). Indeed, depending on the concentration, thrombin can lead to beneficial or 
deleterious outcomes (Vaughan et al., 1995; Pike et al., 1996; Turgeon and Houenou, 1997; 
Turgeon et al., 1998; Choi et al., 2003; Suo et al., 2003; Cannon et al., 2006; Xi et al., 2006; 
Yang et al., 2008; Hua et al., 2009).  
In particular, low concentrations of thrombin (10 pM-10 nM) are neuroprotective in 
ischemic brain and can protect hippocampal neurons and astrocytes from cell death in 
response to oxygen-glucose deprivation (OGD), hypoglycemia, growth supplement 
deprivation and oxidative stress through the activation of PAR-1 (Vaughan et al., 1995; 
Striggow et al., 2000; Wang et al., 2007). Thus, thrombin is investigated if it serves as another 
form of ischemic preconditioning (thrombin preconditioning) and exerts a neuroprotective 
effect in ischemic stroke. Low doses of thrombin improve the outcome to subsequent stroke 
condition via activation of PAR-1 (Xi et al., 1999; Masada et al., 2000; Henrich-Noack et al., 
2006; Granziera et al., 2007). However at high concentration (500 nM), thrombin causes brain 
damage and also exacerbates OGD-induced neuronal death via PAR-1 and PAR-4 (Striggow 
et al., 2000; Junge et al., 2003; Olson et al., 2004; Cuomo et al., 2007; Thevenet et al., 2009; 
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Mao et al., 2010). It also induces delayed neuronal injury in cerebral cortex and shrinkage of 
the striatum in vitro and in vivo (Fujimoto et al., 2006; Fujimoto et al., 2007).  
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1.7 Proteases interaction with NMDA receptors 
One of the mechanisms through which thrombin and PAR-1 mediates excitotoxicity 
in the brain is proposed to involve the release of glutamate from glial cells, which activates 
the NMDA receptors on neighboring neurons (Lee et al., 2007). Recently, many proteases are 
observed to interact directly or indirectly with the NMDA receptors and modulate the 
function of NMDA receptors. Indirect interaction requires proteases to interact with other 
proteins to modulate the NMDA receptors. Direct interaction involves the proteolysis of 
NMDA receptors to change the NMDA receptor function. Proteolysis of the NMDA receptors 
becomes a novel form of post-translational modification of the receptors.  
1.7.1 Cysteine proteases 
An example of cysteine proteases is calpain. Calpain proteolyzes the NR2 subunits at 
the CTD. NR2 proteolysis by calpain is phosphorylation-dependent and is also dependent on 
the MAGUKs the NR2 subunits are binding to (Bi et al., 1998a; Bi et al., 1998b; Bi et al., 
2000; Guttmann et al., 2001; Rong et al., 2001; Simpkins et al., 2003; Wu et al., 2007; Yuen 
et al., 2008). Calpain also cleaves the NMDA receptor binding proteins such as PSD-95, 
cytoskeletal protein spectrin and collapsin response mediator proteins (CRMPs). These 
proteins anchor NMDA receptors at the synapse and are also required for modulating the 
microtubule dynamics at the synapse (Vanderklish et al., 1995; Vinade et al., 2001; Bretin et 
al., 2006).  Thus, although calpain does not change NMDA receptor function, it may regulate 
the turnover of NMDA receptors at the synaptic and extrasynaptic region and affect the 
number of functional receptors expressed on the surface (Vinade et al., 2001; Dong et al., 
2004; Wu et al., 2005; Bretin et al., 2006). As a Ca
2+
-dependent protease, calpain is activated 
by the NMDA receptors. Thus calpain cleavage may represent an autoregulation of NMDA 




1.7.2 Matrix metalloproteinases (MMPs) 
MMP-3 and MMP-7 cleave the NR1 at the LBD (Pauly et al., 2008; Szklarczyk et al., 
2008). MMP-7 cleavage of the NR1 and NR2A decrease the NMDA-mediated Ca
2+
 flux and 
alter the translocation of the NMDA receptors (Szklarczyk et al., 2008). MMPs also modulate 
NMDA receptor function without proteolytic action on the NMDA receptors. MMP-9 
interacts with PKC and accelerates the desensitization and deactivation kinetics without 
affecting the current amplitude (Gorkiewicz et al., 2009). MMP-9 also interacts with the β1-
integrin and increases the surface expression of NMDA receptors through the β1-integrin 
signaling pathway (Michaluk et al., 2009). Interestingly, thrombin also activates pro-MMP9 
and is more prominent in mediating cell death in intracerebral hemorrhage (ICH) compared to 
PAR-1 (Xue et al., 2006; Xue et al., 2009).  
1.7.3 Serine proteases 
Two other serine proteases, tPA and plasmin, that are involved in the modulating the 
blood hemostasis like thrombin, are also found in the CNS. tPA interacts with the liproprotein 
receptor-related protein (LRP1) from the low density lipoprotein receptor family (LDLR). 
The tPA-LRP1 entity interacts with the NMDA receptors via PSD-95 (Martin et al., 2008). 
This enhances the receptor function, with an increase in the surface NMDA receptors 
expression and also an increase in NMDA receptors signaling (Pawlak et al., 2005b; Martin et 
al., 2008; Samson et al., 2008). Enhancement of NMDA receptors function through the NR2B 
and NR2D mediates the neurotoxicity and stress condition via the Erk1/2 and inducible NOS 
(iNOS) (Kilic et al., 2005; Pawlak et al., 2005a; Pawlak et al., 2005b; Norris and Strickland, 
2007; Martin et al., 2008; Baron et al., 2010). Proteolytic action of tPA also modulates the 
NMDA receptors through cleavage of NR1 and plasminogen (Nicole et al., 2001; Fernandez-
Monreal et al., 2004; Pawlak et al., 2005b; Benchenane et al., 2007).  
Activation of plasminogen by tPA generates plasmin which modulates the NMDA 
receptor function through direct cleavage of NMDA receptors or by modulating the 
interacting proteins of NMDA receptors. Plasmin can cleave the NR1, NR2A and NR2B and 
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cause a decrease in the number of surface NMDA receptors expressed and change the number 
of dendritic spines under stress condition (Pawlak et al., 2005a; Pawlak et al., 2005b). 
Plasmin cleaves the NR1 at the Lys
316
 and the Arg
704
 (Samson et al., 2008). It also cleaves the 
NR2A ATD at Lys
317
. Removal of the ATD up to Lys
317
 eliminates the high affinity Zn
2+
 
inhibition. As a result, the NMDA receptor response is also enhanced (Yuan et al., 2009b). 
Plasmin also interacts with PAR-1 to enhance NMDA receptor function through a similar 
mechanism as thrombin, i.e. by activating PAR-1 which results in the release of glutamate 
that can subsequently activates the NMDA receptors (Lee et al., 2007; Mannaioni et al., 
2008).  
Thrombin activation of PAR-1 expressed on astrocytes stimulates the release of Ca
2+
 
from astrocytic intracellular Ca
2+
 stores. The Ca
2+
 then induces the release of glutamate from 
the astrocytes which activates the NMDA receptors (Bowser and Khakh, 2007; Lee et al., 
2007). As a result, this activates the NMDA receptor-mediated component of the synaptic 
miniature excitatory postsynaptic currents (mEPSCs), evoked EPSCs (eEPSCs) and evoked 
excitatory postsynaptic potentials (eEPSPs) in a Mg
2+
-dependent manner. Sustained release of 
glutamate tonically activates the perisynaptic NMDA receptors. These receptors remain 
blocked by tonic Mg
2+
 until the EPSPs in neighboring synapses lead to significant 
depolarization at the spine head. Thus unblocking the perisynaptic NMDA receptors appears 
as an enhancement of NMDA receptor function (Gingrich et al., 2000; Lee et al., 2007; 
Shigetomi et al., 2008). Activation of Src by PAR-1 may also modulate the phosphorylation 
states of NMDA receptor, thereby modulating its activity (Sharp et al., 2008). Enhancement 
of NMDA receptors by PAR-1 mediates the penumbral injury observed in middle cerebral 
artery occlusion (MCAO) rat model and may also play a part in emotionally motivated 
learning (Almonte et al., 2007; Hamill et al., 2009). Thrombin can also interact directly and 
cleave the NR1 but not the NR2A (Gingrich et al., 2000). Thrombin can cleave NR1 from 
cerebellum, cortex, hippocampus, brain stem and striatum after one hour of incubation with 
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high concentration of thrombin (1000-3000 nM). The cleavage of NR1 is likely to be near the 




1.8 Objectives of the study 
The NMDA receptors have been the focus for drug development in the treatment of 
neurological disease such as ischemic stroke. However, these drugs have never succeeded in 
clinical trials for stroke treatment. The failure in correlating with animal studies is 
incomprehensible.  Proteases such as thrombin have been observed to modulate the NMDA 
receptors through direct and indirect interactions with the receptors. However, direct 
interaction with NMDA receptors by thrombin is not characterized and determined. 
 To address this knowledge gap, the objectives of this study are: 
1) To examine if thrombin interact with the NMDA receptors, e.g. NR2B. 
2) To investigate the putative interaction site of the NMDA receptor subunits with thrombin. 
3) To determine if the interaction occur in the ex vivo system. 
4) To determine the possible changes in the NMDA receptor properties upon thrombin 
cleavage. 
In this study, the possibility of direct interaction with other members of the NMDA 
receptors, e.g. NR2B was investigated. Proteins from rat brain lysate (RBL) and synaptic 
plasma membrane (SPM) were used for the cleavage study. NR2B was cleaved by thrombin. 
Next, the putative cleavage site was determined using NR2B recombinant protein fused to the 
maltose binding protein (MBP). Using primary cortical neuronal culture and Xenopus laevis 
oocytes, it was examined if the cleavage of NR2B by thrombin occurs in the native 
conformation. The functional consequences of thrombin cleavage on heterologously 
expressing NR1/NR2B in Xenopus Laevis oocytes was also elucidated using two-electrode 
voltage clamp (TEVC). Taken together, this study provides insights into the consequences of 












Direct interaction of thrombin  
with NMDA receptors 
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2 Direct interaction of thrombin with NMDA receptors 
2.1 Background and objectives  
Emerging evidence have shown the expression of prothrombin (the zymogen form of 
thrombin), FX (the prothrombin activator), PN-1 and antithrombin (the thrombin inhibitors) 
and PARs (the thrombin receptors) in the CNS (Choi et al., 1990; Deschepper et al., 1991; 
Dihanich et al., 1991; Shikamoto and Morita, 1999; Junge et al., 2004). These indicate the 
presence and a role of thrombin in the CNS. During pathological condition such as ischemic 
stroke, expression and activity of thrombin are increased as demonstrated in in vitro and in 
vivo ischemic models (Hua et al., 2003; Karabiyikoglu et al., 2004; de Castro Ribeiro et al., 
2006; Cuomo et al., 2007). This could be due to (1) an increase in thrombin (by increase in 
expression and activation) but an absence of increase in its inhibitors levels and/or (2) an 
extravasation of prothrombin, FX and thrombin when the blood brain barrier is compromised 
(Vaughan et al., 1994; Gingrich and Traynelis, 2000; Riek-Burchardt et al., 2002; Sinnreich et 
al., 2004; Sokolova and Reiser, 2008). Thrombin has been observed to interact with the 
NMDA receptors, either indirectly through PAR-1 or directly via cleavage of NR1 (at very 
high concentration of thrombin, 1000-3000 nM) (Gingrich et al., 2000; Lee et al., 2007). 
NMDA receptors are the major mediators in excitotoxicity during ischemic stroke (Dirnagl et 
al., 1999; Szydlowska and Tymianski, 2010). Interestingly, NR2B-expressing NMDA 
receptors are found to mediate the excitotoxicity (Liu et al., 2007; Chen et al., 2008b). Many 
ischemic drug researches have been made targeting the NR2B subunits. Modulators of the 
NR2B have been relatively well-studied due to their specificity on NR2B. The subtype 
selectivity of these drugs is highly preferred for their ability to minimize the inhibition of all 
NMDA receptors, which under physiological condition, also play an important role in 
neurological development and learning and memory. These NR2B modulators, although 
successful in animal stroke model, are not effective in providing a positive outcome in 
ischemic stroke clinical trials (Nikam and Meltzer, 2002; Gogas, 2006). Up to date, there 
have been observations of various proteases acting as modulators of the NMDA receptors 
through direct interaction with the NMDA receptors in the form of cleavage (Bi et al., 1998b; 
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Gingrich et al., 2000; Guttmann et al., 2001; Nicole et al., 2001; Guttmann et al., 2002; 
Simpkins et al., 2003; Fernandez-Monreal et al., 2004; Wu et al., 2005; Samson et al., 2008; 
Szklarczyk et al., 2008; Yuan et al., 2009b). But there is a lack of investigation with regards 
to thrombin direct interaction with NMDA receptors and if it can be a new form of modulator 
of the NR2B subunits. 
To address this knowledge gap, the objective of this study is to use rat brain lysate 
(RBL) (to examine all NR2B subunits population) or synaptic plasma membrane (SPM) (to 
examine NR2B subunits population expressing on the synaptic membrane surface) from 
Sprague Dawley rats as a source of native NMDA receptors for the investigation of 
interaction with thrombin. Firstly, I sought to establish a method to ensure activity of 
thrombin would be comparable and maintain the same throughout all experiments. Next I aim 
to investigate the possibility of interaction between thrombin and NR2B. Thirdly, the site of 












2.2 Materials and methods 
Materials 
6-8 weeks old male adult Sprague Dawley rats were obtained from the National University of 
Singapore (NUS) Laboratory Animals Centre (LAC) (Singapore). All procedures involving 
animals were approved by the NUS Institutional Animal Care and Use Committee (IACUC). 
Phenylmethylsulphonyl fluoride (PMSF) was purchased from BDH (Dorset, UK). Pepstatin A 
was purchased from Sigma (St Louis, MO, USA). Leupeptin hemisulfate was purchased from 
US Biological (Swampscott, MA, USA). Bicinchoninic acid (BCA) protein assay kit was 
purchased from Pierce (Rockford, IL, USA). pMAL-c2-ATD2B was previously constructed 
by F.M. Ng from our laboratory (Ng et al., 2007). Mutants K318A and R292A were 
previously constructed from the pMAL-c2 ATD2B by J.T. Chen and N. Anthony from our 
laboratory. Amylose resin column was purchased from New England Biolabs (Beverly, MA, 
USA). Thrombin was purchased from Calbiochem (San Diego, CA, USA) and Novagen 
(Madison, WI, USA). Chromogenic substrate of thrombin (Spectrozyme®TH) was purchased 
from American Diagnostica (Greenwich, CT, USA). Thrombin inhibitor D-Phe-Pro-Arg-
chloromethylketone (PPACK) was purchased from Biomol (Plymouth Meeting, PA, USA). 
Protein molecular marker was purchased from Bio-Rad Laboratories (Hercules, CA, USA). 
Anti-NR1 mouse monoclonal antibody (recognizing amino acid residues 660-811 of NR1) 
was purchased from BD Pharmingen (San Diego, CA, USA). N-terminal anti-NR2B rabbit 
polyclonal antibody (recognizing amino acid residues 27-76 of human NR2B) was purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). C-terminal anti-NR2B rabbit 
polyclonal antibody (recognizing amino acid residues 1437-1456 of mature mouse NR2B) 
was purchased from Upstate Biotechnology (Lake Placid, NY, USA). Anti-βIII tubulin mouse 
monoclonal antibody was purchased from Chemicon International Inc. (Temecula, CA, 
USA). For the secondary antibodies, both the goat anti-rabbit and goat anti-mouse 
immunoglobulin G (IgG) horseradish peroxidase antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Enhanced chemiluminescence (ECL) Plus Western 
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blotting detection reagent was purchased from Amersham (Buckinghamshire, UK). All other 
chemicals are purchased from Sigma-Aldrich (St Louis, MO, USA).  
 
RBL preparation 
Brain lysate was obtained by homogenizing Sprague Dawley rat brain in 
radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 1 % Nonidet P-40, 0.5 % 
deoxycholic acid, 50 mM Tris, pH 7.5) in the presence of protease inhibitor (1.5 µM pepstatin 
A and 4.4 µM leupeptin hemisulfate). The brain lysate was then centrifuged at 14000 g for 30 
minutes (min). Supernatant was collected and was centrifuged again at 14000 g for 30 min to 
completely remove debris.  
 
SPM preparation 
SPM preparation protocol was adapted from Rogers et al. (1991) (Rogers et al., 1991). 
Briefly, SPM was prepared from 3-4 g of rat brain blended with 9 volume of dissection buffer 
(10 % (w/v) sucrose, 5 mM EDTA, 50 mM Tris acetate, pH 7.4, 1 mM PMSF, 10 µM 
leupeptin hemisulfate, 1 µM pepstatin A) using a variable speed homogenizer (Glas Col, 
Terre Haute, IN, USA) at 900 revolutions per minute (rpm) for 12-15 strokes. The suspension 
was centrifuged at 800 g for 20 min at 4ºC. The pellet (A) was kept on ice and the supernatant 
was centrifuged in Beckman Type 45 Ti rotor at 16000 g for 30 min at 4ºC. The pellet (B) 
obtained was resuspended in 20 ml of 20 mM HEPES buffer, pH 7.4 and centrifuged at 16000 
g for 4 min at 4ºC. The pellet (C) obtained from this centrifugation step was pooled together 
with pellet (A) and resuspended in 6 volume of lysis buffer (5 mM Tris-acetate, pH 8.1, 10 
µM leupeptin, 1 µM pepstatin). The suspension was left at 4°C for 45 min with constant 
mixing followed by homogenization at 900 rpm for 12-15 strokes using the Glas Col variable 
speed homogenizer. Sucrose and Tris acetate were carefully added to the homogenate to get a 
47 
 
final concentration of 34 % (w/w) sucrose and 50 mM Tris acetate, pH 7.4. Homogenate was 
overlaid with an equal volume of 50 mM Tris acetate, pH 7.4 containing 28.5 % (w/w) 
sucrose and a third volume of 50 mM Tris acetate, pH 7.4 containing 10 % (w/w) sucrose in a 
94-ml tube. The tube was centrifuged at 60000 g for 2 h at 4ºC. The interface between 28.5 % 
and 34 % was collected as SPM. This fraction was diluted to 10 % sucrose with 2 volume of 
50 mM Tris acetate, pH 7.4 and was centrifuged at 48000 g for 30 min at 4ºC. The pellet 
collected was resuspended in 50 mM Tris acetate, pH 7.4, stored at -80ºC and used as SPM 
homogenate.  
 
Expression, purification and concentration of MBP-ATD2B fusion protein and its mutants 
Glycerol stock of MBP-ATD2B, MBP-ATD2B(K318A) and MBP-ATD2B(R292A) were 
prepared by F.M. Ng, J.T. Chen and N. Anthony from our laboratory. Mutant constructs were 
verified by sequencing. Bacteria culture was precultured from the glycerol stock in Luria-
Bertani (LB) broth overnight at 37ºC at 220 rpm. An aliquot of the preculture was inoculated 
into an appropriate volume of LB broth (ratio of preculture to LB broth is 1:10). Bacteria was 
cultured at 37ºC at 220 rpm and the growth of cells were monitored using optical density at 
600 (OD600). When OD600 was between 0.6-0.8, culture was induced with 1 mM IPTG for 5 h 
at 18ºC at 220 rpm. Bacterial cells were lyzed by sonication and the extracts were separated 
by centrifugation at 14000 g for 30 min at 4°C into soluble (supernatant) and insoluble 
(inclusion bodies) fractions. These fractions were analyzed by Coomassie brilliant blue-
stained 15 % sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) gels. The soluble 
fractions were then purified. Typically, 10 mg of protein was loaded into an amylose resin 
column for purification and the bound protein was eluted with 10 mM maltose. The purified 





Measurement of protein concentration 
The protein concentration of RBL or SPM was determined by the BCA protein assay 
according to the manufacturer’s protocol. Bovine serum albumin (BSA) standard (0.025-2 
mg/ml) was reconstituted in the buffer of RBL or SPM (RIPA buffer, pH 7.4 or 50 mM Tris 
Acetate, pH 7.4 respectively). Absorbance was measured at 562 nm. A protein calibration 
graph was generated. Protein concentration of RBL and SPM was based on the calibration 
graph generated.  
The protein concentration of purified MBP-ATD2B was determined by the Bradford 
protein assay. Absorbance was measured at 280 nm. A protein calibration graph was 
generated using 0.2-1 mg/ml BSA. Protein concentration of MBP-ATD2B was based on the 
calibration graph generated.  
 
Thrombin concentration determination 
Lyophilized thrombin was reconstituted using thrombin diluent buffer (10 mM HEPES, 100 
mM NaCl, pH 8.2). Activity of thrombin was measured using the chromogenic substrate, 
Spectrozyme®TH, according to the manufacturer’s protocol. Readings were taken at λ405 nm 
every 30 seconds (s) over a period of 31 min at room temperature. Thrombin concentration 
between 0.1 U/ml to 5 U/ml (i.e. 1 nM to 50 nM) were used to plot a calibration curve of 
initial rate against concentration of thrombin. All subsequent thrombin preparations’ activity 
prior use will be measured and activity will be based on this calibration curve to ensure the 
consistency in the thrombin’s activity used for all experiments. Thrombin in U/ml was 






60 µg of RBL or 50 µg of SPM homogenates or 2-5 µg of purified MBP-ATD2B, MBP-
ATD2B(K318A) and MBP-ATD2B(R292A) were incubated with thrombin (0.1-1000 nM) in 
the presence of cleavage buffer (0.15 M NaCl, 2.5 mM CaCl2, 20 mM Tris-HCl, pH 8.4) at 
37°C. 24 h of thrombin treatment was performed (unless otherwise specified) to ensure 
complete cleavage. Experimental reactions were stopped by boiling in sample buffer (50 mM 
dithiothreitol (DTT), 5% glycerol, 1% SDS, 30 mM Tris-HCl, pH 6.8, 0.0005% bromophenol 
blue).  
 
SDS-PAGE, immunoblotting and densitometry analysis 
Protein was separated by denaturing Laemmli SDS-PAGE using the Hoefer Mighty Small 
Vertical Electrophoresis System (San Francisco, CA, USA). Reactions that were treated with 
thrombin were separated on 8.5 % or 15 % SDS-PAGE gel. Protein was stained and 
visualized using Coomassie brilliant blue R-250. For Western blotting, protein was 
electrophoresed and transferred onto polyvinyldine difluoride (PVDF) membranes in transfer 
buffer (10 % methanol, 25 mM Tris, 192 mM glycine) for 19 h at 30 V at 4C. Membranes 
were blocked in 5% non-fat milk in Tris-buffered saline containing 0.1% Tween-20 for 1 h on 
a shaker at room temperature. They were incubated with either N-terminal anti-NR2B (1 : 
200) or C-terminal anti-NR2B (1 : 800) or anti-NR1 antibody (1 : 2000) or anti-βIII tubulin 
antibody (1 : 1000) primary antibodies. Membranes were washed 3 times, each time of 10 
min, in Tris-buffered saline containing 0.1% Tween-20. They were then incubated with anti-
rabbit IgG horseradish peroxidase (1 : 20000) or anti-mouse IgG horseradish peroxidase (1 : 
5000), washed again, and subsequently detected by ECL Plus. Densitometry analysis was 




Sequencing of NR2BATD Thrombin Cleavage Products 
The protein was separated by gel electrophoresis, blotted onto PVDF membrane, and stained 
with Coomassie Brilliant Blue R-250. The N-terminal sequence after thrombin cleavage was 
determined using Edman degradation in a protein sequencer (Perkin Elmer Applied 
Biosystems, Foster City, CA, USA) performed by Midwest Analytical (St Louis, MO, USA). 
 
Illustration of crystal structure of NR2B ATD 
The apo-crystal structure of NR2B ATD (Protein Data Bank code 3JPW) provided the 
structural template to create the images using Protein Workshop (Karakas et al., 2009).  
 
Data analysis 
Data were expressed as mean ± standard error of the mean (S.E.M.) and analyzed statistically 
using one-way analysis of variance (ANOVA) followed by post-hoc Dunnett test. 
Significance for all tests was set at P < 0.05. Error bars in figures were S.E.M. Graphs were 





Thrombin activity calibration 
In order to ensure that thrombin concentration was comparable across experiments, a 
thrombin calibration curve was generated. Chromogenic substrate specific for thrombin was 
used (Sonder and Fenton, 1986). Initial rate of the hydrolysis of the substrates was determined 
from the linear portion of the saturation-kinetics plots (Fig. 2.1A). The initial rate of 
hydrolysis was the slope gradient of the linear phase. A range of thrombin concentration 
(from 0.05-500 nM) was used. However, hydrolysis rates of the chromogenic substrates by 
0.05 nM, 0.1 nM, 0.5 nM thrombin were too low for detection (Fig. 2.1A). For 100 nM, 500 
nM, 750 nM, 1000 nM and 5000 nM of thrombin, the hydrolysis rates were too fast to be 
accurately measured (Fig. 2.1A). Thus only the linear slope gradients of 1-50 nM of thrombin 
were used for generating the thrombin calibration graph (Fig. 2.1A and Fig. 2.1B). As the rate 
of hydrolysis was proportional to the concentration of the reactant (thrombin), a first order 
reaction graph was produced (Fig. 2.1B). Using the equation of the plot, y = 1.5 x 10
-5 
x - 6.8 
x 10
-6
 (whereby y is the rate of hydrolysis and x is the concentration of thrombin), the 
concentration of every new vial of thrombin to be used can be deduced based the rate of 
hydrolysis measured. With this, all thrombin used, regardless of batch, could be kept similar 





Fig. 2.1. Generation of thrombin calibration curve. (A) Saturation-kinetics plot of different 
concentration of thrombin. Only the first 1500 s were shown for clearer presentation. Thr 
indicates thrombin. Concentration of thrombin is as color coded. Some of the reactions 
required some time to stabilize (e.g. 0.5 nM and 3 nM of thrombin). Rate of hydrolysis of the 
substrates was taken from the linear phase, i.e. 250 s and after. Rate of hydrolysis was too low 
and too high to be measured accurately at 0.5 nM and 100 nM thrombin respectively. Thus, 
only 1-50 nM thrombin were used for the generation of the thrombin calibration curve. (B) 
Rate of hydrolysis was plotted against thrombin concentration. Values were mean ± S.E.M. 
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Interaction of thrombin and NR2B 
RBL was incubated in increasing concentration of thrombin (0.1-1000 nM) for 24 h and 
analyzed by Western blots using an C-terminal and an N-terminal anti-NR2B (Fig. 2.4A) 
(Rao et al., 1998; Wong et al., 2005). We showed thrombin, in a concentration-dependent 
manner, caused (1) a decrease in the immunoreactivity of the full-length 180 kDa NR2B 
band, and (2) an increase in the immunoreactivity of a new ~150 kDa band detected by the C-
terminal anti-NR2B (at 1 nM and higher thrombin concentrations; n=3; Fig. 2.4B, top panel). 
Concurrently, the other cleaved ~30 kDa fragment was detected with an N-terminal anti-
NR2B (Fig. 2.4B, middle panel). Their parallel increase in immunoreactivity corresponded to 
the decrease in full-length NR2B immunoreactivity. At low thrombin concentration (1 nM), 
up to 80 % of the full-length NR2B was cleaved (Fig. 2.4C). At a high concentration (1000 
nM thrombin), it was observed that the 150 kDa and 30 kDa smaller fragments also decreased 
in intensity. This may be a result of non-specific cleavage by high concentration of thrombin 
(1000 nM) for long exposure (24 h).  However, it should be taken into consideration that the 
generation of the two smaller fragments, 150 kDa and 30 kDa fragments, is thrombin specific 
as saturated concentration of 120 µM thrombin irreversible inhibitor, PPACK, completely 
blocked thrombin-induced cleavage of NR2B, validating that the specificity of thrombin 
proteolytic action (Fig. 2.2 and Fig. 2.4B).  
We also investigated if thrombin can cleave the NR2B localized on the synaptic 
membrane. The SPM that was to be used for investigation was characterized. As expected, 
NMDA receptors (NR1 and NR2B) were more enriched in the SPM fraction compared to the 
RBL (Fig. 2.3) (Perez-Otano et al., 2006).  Thrombin also cleaved NR2B localized at the 
synaptic membrane and in a time dependent manner as indicated by the decrease in full length 
NR2B immunoreactivity with increasing time of incubation in 10 nM of thrombin (Fig. 
2.4D). Based on the molecular weight of the cleaved fragments detected with C-terminal and 
N-terminal anti-NR2B, the thrombin cleavage of the NR2B subunit were deduced to occur at 





Fig. 2.2. Characterization of thrombin inhibitor. PPACK inhibited the action of thrombin. 
Only the first 1500 s were shown for clearer presentation. 5 µM of PPACK was sufficient in 
inhibiting the hydrolysis action of the chromogenic substrates by 10 nM thrombin. Values 





Fig. 2.3. Characterization of SPM. Equal amount (50 µg) of SPM and RBL were analyzed 
by western blot. NR1 and NR2B were more enriched in SPM fraction compared to RBL. 




Fig. 2.4. Thrombin cleaves the NR2B subunit from RBL and SPM. (A) Diagram showing 
the cleavage site (arrow) based on the fragment sizes. The dotted line and the solid line 
represent the epitope to which the N-terminal and C-terminal anti-NR2B recognized 
respectively. Gray rectangular box indicates the linker between ATD and S1. Black 
rectangular boxes indicate the transmembrane domain (M1, M3 and M4) and the re-entrant 
loop (M2). Domains are as indicated. Molecular weight (in kDa) of the NR2B protein and the 
cleaved of fragments are indicated. (B-D) Thrombin is indicated as Thr. Molecular weight (in 
kDa) of the NR2B protein and the fragments are as indicated. (B) Thrombin cleaved NR2B 
protein in RBL. A 150 kDa (top panel) and a 30 kDa (middle panel) fragments were detected 
with an C-terminal and N-terminal anti-NR2B respectively upon 24 h of thrombin treatment. 
Cleavage was blocked by PPACK (120 µM) (n=3). (Bottom panel) Tubulin acted as the 
loading control. (C) Immunoreactivity quantification of full-length NR2B for the indicated 
treatment. Data (mean ± S.E.M.) were expressed in terms of percentage of initial substrate 
densitometry. * indicated P < 0.01 (one-way ANOVA, post-hoc Dunnett test). (D) Thrombin 
cleaved NR2B from SPM in a time-dependent manner. SPM was incubated in 10 nM of 
thrombin with increasing time of incubation. A smaller band of 150 kDa was detected by an 





Identification of cleavage site 
Based on epitope mapping and the fragment sizes observed, it is hypothesized that the 
cleavage site is at the ATD (Fig. 2.4A). To investigate the thrombin cleavage site on NR2B, 
soluble recombinant fusion MBP-ATD2B protein (~85 kDa) was subjected to the same 
cleavage conditions as the RBL. At low concentration of thrombin (1 nM), MBP-ATD2B was 
cleaved, yielding a ~75 kDa band that could be detected by the N-terminal anti-NR2B. This 
cleavage was blocked by PPACK (Fig. 2.5A, upper panel). We isolated the smaller fragment 
(~10 kDa) (Fig. 2.5A, lower panel) and subjected the protein fragment to N-terminal 





SCYNTHE; Fig. 2.5B; underlined and italic amino acids). This observation 
suggested thrombin cleaved NR2BATD after residue 318 (Fig. 2.5C). To verify that Lys
318
 is 
the thrombin cleavage site on ATD of NR2B, Lys
318
 was mutated to alanine on MBP-ATD2B 
(MBP-ATD2B(K318A)) and subjected to thrombin cleavage. At the highest thrombin 
concentration tested (10 nM), there was no detectable cleavage of recombinant MBP-
ATD2B(K318A) protein and no detection of the ~75 kDa band (Fig. 2.5D). Previously, Perin-
Dureau et al. (2002) speculated that Arg
292
 could be a putative thrombin cleavage site (Perin-
Dureau et al., 2002b). Under the same thrombin treatment conditions as MBP-ATD2B, MBP-
ATD2B(R292A) mutant fusion protein produced the same cleaved off fragment (~75 kDa) as 
the wild-type MBP-ATD2B, thus suggesting that Arg
292
 may not be a thrombin cleavage site 
on NR2B ATD (Fig. 2.5E). This is also consistent with the crystal structure of the ATD 
NR2B, where the Arg
292






Fig. 2.5. Thrombin cleaves NR2BATD recombinant protein. (A-E) Thrombin is represented 
as Thr. Molecular weight (in kDa) of the protein and the fragments are as indicated. (A) (Top 
panel) Cleavage of MBP-ATD2B yielded a smaller fragment of 75 kDa detected by N-
terminal anti-NR2B (n=3). (Bottom panel) Coomassie blue-stained gel showed the other 
smaller fragment of 10 kDa (n=2). The band below the 10 kDa fragment was contributed by 
1000 nM of thrombin. (B) Lys
318
 (highlighted in gray) was the thrombin cleavage site. The 
underlined and italic amino acids were determined from N-terminal sequencing on the 
cleaved 10 kDa protein fragment (see Fig. 2.5A, bottom panel). (C) Diagram of the 
recombinant MBP-ATD2B fusion protein and the thrombin-cleaved fragments.  indicates 
the thrombin cleavage site. (D) Absence of thrombin cleavage on MBP-ATD2B(K318A) 
mutant protein (n=3). (E) Cleavage of MBP-ATD2B(R292A) yielded a smaller fragment of 
75 kDa (n=3) indicating that Arg
292







Thus far, the identified thrombin cleavage site (Lys
318
) on NR2B ATD was consistent 
with other thrombin substrates where thrombin cleavage sites were mostly basic and 
positively charged (Fig. 2.5B and Table 2.1) (Leavis et al., 1978; Francois et al., 1995; 
Ishihara et al., 1997; Huntington, 2005). Coincidentally, all known critical residues that exert 











, were located upstream and distant 
from the thrombin cleavage site Lys
318
 on NR2B ATD (Fig. 2.6A) (Perin-Dureau et al., 2002b; 
Mony et al., 2009c; Wee et al., 2010). Thus binding of ifenprodil or its analogue, RO25,6981, 




Fig. 2.6. Cleavage site is located away from the binding pocket of ifenprodil and its 
analogues. (A) Ribbon representation of the apo-NR2B ATD structure (3JPW) generated 
using Protein Workshop. The clam-shell structure of the NR2B ATD is made up of two 
domains, R1 (blue) and R2 (magenta). Secondary structures are as labeled (Karakas et al., 
2009). NT indicates N-terminal while CT indicates C-terminal. The disordered region 











involved in ifenprodil inhibition are colored green. Lys
318
 (yellow) is located at the top of R1. 
Arg
292 
(red) lies hidden inside the cleft. (B) NR2B antagonists binding to the pocket did not 
prevent cleavage by thrombin. NR2B specific antagonists (ifenprodil and RO25,6981), at 
their respective concentration, were incubated with 50 µg of SPM for 30 min before the 
addition of 10 nM thrombin for 3 h cleavage treatment. Immunoblot was detected with an 
antibody recognizing the C-terminal of NR2B. A smaller band of 150 kDa was observed. 





Possibility of interaction: localization 
Thrombin cleaved the Lys
318
 of the NR2B ATD located extracellularly. The possibility for 
contact between thrombin and NR2B becomes crucial. Cleavage of NR2B by thrombin is 
possible only if thrombin is located extracellularly in the brain parenchyma. 
Immunoreactivity for prothrombin has been observed in pyramidal neurons in the temporal 
cortex, capillaries of brain tissue and astrocytes (Deschepper et al., 1991; Arai et al., 2006; 
Yin et al., 2010). Thrombin activity is observed in serum-free culture medium bathing 
hippocampal slices (Thevenet et al., 2009). Modeling after the hepatocytes, the major site of 
prothrombin synthesis, prothrombin is proposed to be released by neurons and astrocytes in 
the CNS and subsequently activated by FX to thrombin (Deschepper et al., 1991; Saucan and 
Palade, 1994; Bristol et al., 1996; Yamada and Nagai, 1996; Davie and Kulman, 2006). The 
method of prothrombin release at the CNS, i.e. constitutive or regulated, is currently 
unknown, but the level of extracellular, active thrombin is regulated by CNS-derived ATIII or 
PNI (Choi et al., 1990; Deschepper et al., 1991; Vaughan et al., 1994; Niclou et al., 1998). In 
particular, extracellular thrombin activity increases significantly after OGD and ICH (Gong et 
al., 2008; Thevenet et al., 2009). In addition to local synthesis and secretion from neurons, 
astrocytes and endothelial cells, thrombin originating from the blood, may also enter into the 
brain parenchyma in the form of prothrombin in the cerebrospinal fluid (CSF) (Smirnova et 
al., 1997; Lewczuk et al., 1998). Thus, the localization of extracellular, active thrombin 




Possibility of interaction: molecular recognition 
The ability of thrombin to recognize Lys
318
 on NR2B is also important for successful 
cleavage. Thrombin recognizes molecular patterns for cleavage (Table 1.2). Basic, positive 
residues such as Arg (R) or Lys (K) at the P1 site forms an ionic interaction with Asp
199
 at the 
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S1 subsite of thrombin, determining the specificity (Davie and Kulman, 2006). However, 
based on thrombin crystal structure analysis and mutagenesis studies, the active site groove is 
surrounded by the 60 loop and the γ-loop, restricting access to potential substrates (Bode et 
al., 1989; Bode et al., 1992; Le Bonniec et al., 1992; Le Bonniec et al., 1993). Thus, the 
kinetic behavior is largely contributed by the side chain of surrounding amino acids on the 
substrates (Lottenberg et al., 1983).  Looking at the two amino acids adjacent to the cleavage 
recognition site of NR2B, i.e. P2 and P1’, they are well conserved and consistent with other 
P2 and P1’ of other thrombin substrates (Table 2.1) (Leavis et al., 1978; Francois et al., 1995; 
Ishihara et al., 1997; Huntington, 2005). The pyrrolidine ring of Pro
317
 (P) of NR2B (P2 
position), like many natural substrates of thrombin, allows excellent packing by the phenolic 
side chain of Tyr60A at the 60 loop (Table 2.1). Larger residues will not pack favorably into 
the S2 subsite of the thrombin cavity and smaller residues (e.g. Gly) will not fit as well (Bode 
et al., 1992; Huntington, 2005). In particular, the S1’ site is restricted by the 60 loop, 
preferring small residues with polar side chain. Ser
319 (S) at P1’ position of NR2B ATD is a 
small residue with polar side chains (Lottenberg et al., 1983; Bode et al., 1989; Bode et al., 
1992; Rezaie and Olson, 1997). This may explain that although the Lys
317
 is conserved in 
NR2A, no cleavage of NR2A by thrombin was observed due to the absence of Pro at the 316
th
 
residue and the presence of a non, polar Ala at the 318
th






Table 2.1. Alignment of thrombin cleavage sites of known natural substrates. The terms 
P4, P3, P2, P1, P1’, P2’ and P3’ describe the substrate peptide amino acid positions relative to 
the P1–P1’ bond. Amino acids are represented by their one-letter amino acid code. Thrombin 
recognizes basic and positive residues (yellow) and cleaves at the bond between P1 and P1’. 
Pro (P) (cyan) are conserved at P2 and Ser (S) (orange) are small residue with polar side 
chains that are conserved at the P1’.  
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Possibility for interaction: structure 
I have shown thrombin cleavage of NR2B in brain homogenate, SPM fraction and 
recombinant proteins. NR2B from such preparations may give an outlook on the possibility 
for interaction. It also allows us to identify the site of interaction (Lys
318
) accurately. However 
it may misrepresent the real situation. Bearing in mind, NR2B exists as a quaternary structure, 
forming a heterotetramer complex with NR1 subunits. Based on the recent quaternary crystal 
structure of a close relative of the NMDA receptors, GluR2, there are numerous interface 
within a dimer, between two dimers and also between domains (Sobolevsky et al., 2009). 
From the analysis on the heterodimer of NR1-NR2A LBD crystal structure, the heterodimer 
buries 2640 Å of solvent accessible surface area (Furukawa et al., 2005). Mutagenesis studies 
also demonstrate contacts are formed between domain, e.g. ATD with LBD (Zheng et al., 
2001; Gielen et al., 2008; Gielen et al., 2009; Yuan et al., 2009a). In the event that Lys
318
 of 
NR2B is located at such solvent inaccessible surface, interaction with thrombin would 
become unfeasible. Homogenizing procedures in lysis buffer could have disrupted the NR2B 
structure exposing cleavage sites that may be natively inaccessible to thrombin. Thus, it is 
crucial to carry out investigations on whether thrombin interaction with NR2B occurs in the 
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3 Ex vivo and electrophysiological demonstration of thrombin interaction with NR2B 
3.1 Background and objectives 
In Chapter 2, I have reported the direct thrombin cleavage of NR2B at the Lys
318
 at the 
ATD. This was demonstrated using RBL, SPM and recombinant NR2BATD proteins. The use 
of detergents to solubilize the NR2B subunits from RBL and also the expression of solely the 
ATD of NR2B produce NR2B subunits that may not be full representations of how NR2B 
exists in a quaternary NMDA receptor structure. Thus, an objective of the study would be to 
determine if the cleavage by thrombin occurs on NR2B expressed in a NMDA receptor 
complex in cortical neuronal cultures.  
NR2B-expressing NMDA receptors are important mediators of excitotoxicity in 
ischemic stroke (Liu et al., 2007; Chen et al., 2008a). During ischemic stroke, a decrease in 
the blood flow will lead to an increase in synaptic glutamate levels and a reducing milieu 
(Yager et al., 1991; Anderson et al., 1999; Chen and Shi, 2008). To briefly illustrate, the 
redox environment is determined by the overall states contributed by the oxidized and 
reduced states of a number of redox couples, such as i) NADP
+
 and NADPH, ii) NAD
+
 and 
NADH and iii) GSSG and GSH (Mayevsky and Chance, 2007; Kakaç et al., 2010). Indeed, 
during ischemic stroke, a situation that results in a low glucose and oxygen supply to the 
brain, the reduced states of these redox couples are found to be increased, resulting in a 
reducing milieu (Tanaka et al., 1986; Yager et al., 1991; Anderson et al., 1999; Shi and Liu, 
2006).  It is observed that a reducing milieu changes the NMDA receptors through the 
modulation at the redox sites (Aizenman et al., 1989; Tang and Aizenman, 1993; 
Brimecombe et al., 1999; Choi et al., 2001; Takahashi et al., 2007). This may have an 
implication on the interaction with thrombin. Thus, in this study, we also mimic the reducing 
condition during ischemic stroke using a reducing agent, DTT, and investigate if under such 




3.2 Materials and methods 
E18 Sprague Dawley rat embryos were obtained from LAC (Singapore) with procedures 
approval by IACUC (Singapore). Trypsin, deoxyribonuclease (DNase), dialyzed heat-
inactivated fetal bovine serum (FBS), Hank’s balanced salts solution (HBSS), penicillin-
streptomycin, poly-D-lysine, cytosine-β-D-arabino-furanoside, BSA, Gel Mount, ethyl 3-
aminobenzoate methanesulfonate salt (MS-222), collagenase, glutamate and ifenprodil were 
purchased from Sigma (St Louis, MO, USA). Neurobasal medium, B27 supplement, sodium 
pyruvate and HEPES were purchased from Invitrogen (Carlsbad, CA, USA). GlutaMAX-1 
was purchased from Gibco (Eggenstein, Germany). Anti-βIII tubulin TUJ1 mouse 
monoclonal antibody was purchased from Covance (Madison, WI, USA). Anti-glial fibrillary 
acidic protein (GFAP) rabbit polyclonal antibody was purchased from DAKO (Carpinteria, 
CA, USA). Anti-NR1 goat polyclonal antibody (recognizing the C-terminus of human NR1) 
was purchased from Santa Cruz (Santa Cruz, CA, USA). N-terminal anti-NR2B rabbit 
polyclonal (recognizing amino acid residues 323-337 of rat NR2B) for immunocytochemistry 
was purchased from Alomone Labs (Jerusalem, Israel). C-terminal anti-NR2B rabbit 
polyclonal antibody (recognizing amino acid residues 1437-1456 of mature mouse NR2B) for 
western blot was purchased from Upstate Biotechnology (Lake Placid, NY, USA). Anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mouse monoclonal antibody was 
purchased from Chemicon International Inc. (Temecula, CA, USA). For the secondary 
antibodies used in immunocytochemistry, donkey anti-rabbit Alexa Fluor 488, donkey anti-
goat Alexa Fluor 594 and donkey anti-mouse Alexa Fluor 647 were purchased from 
Molecular Probes (Eugene, OR, USA). For the secondary antibodies used in western blot, 
both the goat anti-rabbit and goat anti-mouse IgG horseradish peroxidase antibodies were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Thrombin was purchased 
from Calbiochem (San Diego, CA, USA). Protein molecular marker and DTT were purchased 
from Bio-Rad Laboratories (Hercules, CA, USA). ECL Plus was purchased from Amersham 
(Buckinghamshire, UK). Xenopus laevis frogs were obtained from Xenopus Express 
(Vernassal, France). pCIneo NR1-1a and pcDNA1 NR2B were gifts from Dr. S.F. 
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Heinemann. pcDNA1 NR2B(K318A) was constructed by J.T. Chen and N. Anthony from our 
laboratory. Restriction enzymes were purchased from New England Biolabs (Beverly, MA, 
USA). QIAquick gel extraction kit was purchased from Qiagen (Valencia, CA, USA). 
mMESSAGE mMACHINE T7 kit was purchased from Ambion (Austin, TX, USA). RNA 
ladder was purchased from Fermentas (Vilnius, Lithuania). Glycine was purchased from 
AppliChem (Darmstadt, Germany). Chromogenic substrate of thrombin (Spectrozyme®TH), 
PMSF, pepstatin A and leupeptin hemisulfate were purchased from companies as stated in 
Chapter 2. All chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA).  
 
Cortical neuronal culture 
Primary cultures of cerebrocortical neurons were obtained from E18 Sprague Dawley rat 
embryos. Cortices were aseptically dissected from the brains. The meninges and the choroid 
plexus were carefully removed under a dissecting microscope (Nikon SMZ645, Tokyo, 
Japan) performed in a Class I laminar flow hood. Cortical tissues were digested in 0.2 mg/ml 
trypsin and 40 µg/ml of DNase in HBSS supplemented with 7.4 mM glucose, 1 mM sodium 
pyruvate, 10 mM HEPES, 4.2 mM NaHCO3, 1.2 mM MgSO4 and 0.3 % (w/v) BSA at 37°C 
for 5 min followed by mechanical trituration. Dissociated cells were harvested by 
centrifugation and resuspended in Neurobasal medium supplemented with 10 % (v/v) 
dialyzed heat-inactivated FBS, 2.5 % (v/v) B27 supplement, 2 mM GlutaMAX-1 and 1 % 
(v/v) penicillin-streptomycin. Cells were seeded at a density of 0.5 x 10
6
 cells in 24-well 
plates or nitric-acid treated glass coverslips, both coated with 0.1 mg/ml poly-D-lysine before 
plating. Cells were then cultured at 37°C in a humidified 5 % CO2 incubator. Culture medium 
was replaced with the above Neurobasal medium and their supplements but in the absence of 
FBS a day later. 10 µM of cytosine-β-D-arabino-furanoside was added on day-in-vitro 4 





DIV11 cultures were fixed in 4 % (w/v) paraformaldehyde for 15 min at 4°C. The cells were 
washed in phosphate buffered saline supplemented with 0.1 % (v/v) Triton X-100 (PBS-Tx). 
This was followed by blocking in 3 % (w/v) BSA in PBS-Tx for 1 h at room temperature. 
Subsequently, the cells were incubated with anti-βIII tubulin TUJ1 (1 : 500) or anti-GFAP (1 : 
2000) or anti-NR1 (1 : 100) or N-terminal anti-NR2B (1 : 100) for 24 h at 4°C and washed 3 
times, each time of 5 min in PBS-Tx. The cells were then incubated with anti-rabbit Alexa 
Fluor 488 (1 : 400) or anti-goat Alexa Fluor 594 (1 : 400) or anti-mouse Alexa Fluor 647 (1 : 
400) in the dark for 1 h at room temperature. The cells were washed again and mounted on 
glass slides using Gel Mount aqueous mounting medium.  
 
Confocal microscopy 
Fluorescent images were viewed and captured using a Zeiss LSM510 confocal microscope 
(Carl Zeiss, Gӧttingen, Germany) equipped with an Argon laser of 488 nm, HeNe laser of 543 
nm and 633 nm. Alexa Fluor 488 was viewed with 505-530 nm BP filters. Alexa Fluor 594 
was viewed using 560-615 nm BP filters and Alexa Fluor 647 was viewed using 650 nm BP 
filters. Images were viewed using a pinhole of 1.0 Airy units and objectives of 20x (0.5 NA), 
40x (1.3 NA) or 63x (1.4 NA). Addition of scale bars and image brightness/contrast 
adjustments were performed on the Zeiss LSM Image Browser Software, version 4.0.0.157. 
Images were subsequently exported to TIFF format and assembled by Adobe Photoshop. 
 
Thrombin concentration determination 
Lyophilized thrombin was reconstituted and activity was measured using Spectrozyme®TH 
as depicted in Chapter 2. Initial rate of hydrolysis was determined from the linear portion of 
the saturation kinetics plot. Concentration of the newly constituted vial of thrombin was 
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determined using the plot and the equation y = 1.5 x 10
-5 
x - 6.8 x 10
-6
 obtained in Chapter 2 
(Fig. 2.1B), where y is the rate of hydrolysis and x is the concentration of thrombin.  
 
Thrombin treatment on neuronal culture 
Cultures were treated with thrombin (0.l-1000 nM) on DIV 11 in balanced salt solution (in 
mM): 140 NaCl, 5 KCl, 2 CaCl2, 10 HEPES, 3 D-glucose, pH 7.4 for 2 h at 37°C. Cells were 
washed three times with phosphate buffered saline (PBS, pH 7.4), removed using rubber cell 
scraper, centrifuged at 14000 g for 5 min and the cell pellet was lyzed in RIPA (contents 
described in Chapter 2) to obtain the whole cell homogenate. Protein concentration was 
measured. Protein was analyzed on 8.5 % SDS-PAGE and western blot. Negative controls 
that had thrombin replaced by thrombin diluents (contents described in Chapter 2) and 
thrombin inhibitor, PPACK, were included. 
 
Measurement of protein concentration  
Measurement of protein concentration of cortical neuronal homogenate was performed using 
BCA protein assay as described in Chapter 2. BSA standard was reconstituted in RIPA. 
Absorbance was measured at 562 nm.  
 
SDS-PAGE and immunoblotting  
The protein was separated by SDS-PAGE and analyzed by immunoblotting as described in 
Chapter 2. Immunoblotting was performed using C-terminal anti-NR2B (1 : 800) or anti-
GAPDH (1 : 50000). Detection of primary antibodies was performed using anti-rabbit IgG 
horseradish (1 : 20000) or anti-mouse IgG horseradish peroxidase (1 : 50000) followed by 
ECL Plus.  
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Harvesting Xenopus laevis oocytes 
Stage V/VI oocytes were surgically removed from the ovaries of Xenopus laevis frogs 
anesthetized with 1 g/l MS-222. Clusters of oocytes were incubated with 2 mg/ml collagenase 
for 2 h in Ca
2+
-free solution comprised of (in mM) 115 NaCl, 2.5 KCl, and 10 HEPES, pH 
7.5, with slow agitation to remove the follicular cell layer. Oocytes were then washed 
extensively in the same solution supplemented with 1.8 mM CaCl2 and maintained in Barth’s 
solution comprised of (in mM): 88 NaCl, 1 KCl, 24 NaHCO3, 10 HEPES, 0.82 MgSO4, 0.33 
Ca(NO3)2 , and 0.91 CaCl2 and supplemented with 100 mg/ml gentamycin, 40 mg/ml 
streptomycin, and 50 mg/ml penicillin in a 17°C incubator. 
 
Expression of NR1/NR2 receptors in Xenopus oocytes  
pCIneo NR1-1a, pcDNA1 NR2B and pcDNA1 NR2B(K318A) plasmid DNA were linearized 
using NotI. Linearized DNA was analyzed in preparative 0.8 % agarose gel electrophoresis 
and purified using QIAquick gel extraction kit according the manufacturer’s protocol. 
Purified, linearized DNA was used to generate RNA using the mMESSAGE mMACHINE T7 
kit according to the manufacturer’s protocol. Quality of RNA was analyzed using analytical 
0.6 % agarose gel electrophoresis and quantity was measured using ND-1000 
spectrophotometer (NanoDrop Technologies, Montchanin, DE, USA). Oocytes were injected 
under the magnification of SMZ435 dissecting scope (Nikon, Tokyo, Japan) after 24 h of 
isolation. Oocytes were injected with 10-15 ng of RNA in a 50 nl volume using oocyte 
microinjection pipet (Drummond Scientific, Broomall, PA, USA) mounted on a Marzhauser 
MM33 micromanipulator (SDR, Sydney, Australia). The ratio of NR1 to NR2 was at 3:7. 





Two-Electrode Voltage-Clamp (TEVC) Recordings from Xenopus Oocytes 
TEVC recordings on oocytes were as described previously (Traynelis et al., 1998; Low et al., 
2000). Recordings were performed 2-8 days post injection at room temperature using oocyte 
clamp OC-725C (Warner Instruments, Hamden, CT, USA). Oocytes were placed in a custom-
made dual-track recording chamber with a single perfusion line that split to perfuse two 
oocytes. The bath clamps communicated across Ag-AgCl2 pellets (Warner Instruments, 
Hamden, CT, USA) placed at each side of the recording chamber, both of which were 
assumed to be at a reference potential of 0 mV. The recording solution contained (in mM): 90 
NaCl, 1 KCl, 10 HEPES, 0.5 BaCl2, pH adjusted to 7.3 with 5 N NaOH. Solution exchange 
was computer-controlled through a 8-modular valve positioner (Hamilton, Reno, NV, USA) 
using the EasyOocyte software (a gift from Dr. S.F. Traynelis). Voltage and current 
electrodes had a resistance of 2-8 M when filled with 0.3 and 3.0 M KCl, respectively. 
Saturating concentration of glutamate and glycine (30-100 µM) and 0.03-10 µM ifenprodil 
were used in all oocytes experiments unless otherwise stated. Current responses were elicited 
with agonists, in the presence or absence of ifenprodil for 1 min and recorded at a holding 
potential of -20 to -60 mV. Only currents greater than 50 nA were included in the analysis. 
Steady-state currents were obtained for 0.3–10 M ifenprodil and near steady-state currents 
were obtained for 0.03-0.1 M ifenprodil (Perin-Dureau et al., 2002b). Ifenprodil inhibition 
data points were fitted to the equation: 
Percent response = (100 – minimum) / (1 + ([ifenprodil]/IC50)
n
) + minimum  
obtaining the ifenprodil inhibition curves where minimum is a residual current response, IC50 
is the concentration of ifenprodil that produces 50 % of the maximal inhibition and n is the 





Determination of thrombin activity in the presence of DTT 
Rate of hydrolysis of thrombin in the presence and absence of DTT were also determined in 
the same manner as above. However, thrombin was incubated with 3 mM DTT before the 
addition of Spectrozyme®TH. The vehicle for DTT was ultrapure water. 3 mM DTT did not 
interfere with Spectrozyme®TH. 3 mM DTT (saturating concentration for inducing reduction 
action on NMDA receptors) was used to investigate interference on thrombin activity (Tang 
and Aizenman, 1993).   
 
Thrombin treatment on oocytes 
Oocytes were treated with ±thrombin/±DTT, followed by a wash out of drugs as stated in 
(Fig. 3.3A). Vehicle for DTT was the recording solution and that for thrombin was the 
thrombin diluent. Treatment was carried out with TEVC recording in real time. % maximum 
response was carried out in saturating concentration of glutamate and glycine (100 µM each) 
and 0.1 µM, 1 µM and 10 µM of ifenprodil.  
 
Illustration of crystal structure of NR2B ATD 
The apo-crystal structure of NR2B ATD (Protein Data Bank code 3JPW) provided the 
structural template to create the images using Protein Workshop (Karakas et al., 2009).  
 
Data analysis 
Data were expressed as mean ± S.E.M. and analyzed statistically using paired T-test or one-
way ANOVA followed by post-hoc Tukey test. Significance for all tests was set at P < 0.05. 
Error bars in figures were S.E.M. Graphs were plotted using GraphPad PRISM® Version 4.  
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3.3 Results  
In situ proteolysis of native NR2B in primary rat cortical neurons  
To investigate if thrombin can interact and cleave the NR2B ATD in the native quaternary 
heteromeric structure, E18 cortical neuronal culture was used. E18 cortical neuronal culture 
was chosen because cortical neurons have the highest expression of NR2B at that 
developmental stage (Monyer et al., 1994). Culturing condition was optimized such that it 
favored the growth and development of neurons with minimal contamination from glia (less 
than 5 % glia) (Fig. 3.1A) (Wee et al., 2010). DIV11 neuronal culture obtained also showed 
NR1 and NR2B receptors colocalizing with each other (Fig. 3.1B-E). They were surface 
receptors, with the ability to develop as clusters along dendrites, starting from the soma (Fig. 
3.1F-G) (Li et al., 1998a; Rao et al., 1998; Cottrell et al., 2000; Washbourne et al., 2004). 
Thrombin treatment was performed on these cortical neuronal cultures by incubating neurons 
in increasing concentration of thrombin (0.1-1000 nM), in situ, for 2 h at 37C. With 
increasing thrombin concentration, ~150 kDa protein fragments that were immunoreactive to 
C-terminal anti-NR2B were detected (Fig. 3.2) (albeit was less efficient compared to 
experiments with RBL, SPM and recombinant NR2BATD; Fig. 2.4B, Fig. 2.4C, Fig. 2.4D, Fig. 
2.5A and Fig. 2.6B in Chapter 2). The appearance of the cleaved ~150 kDa fragment was 
accompanied by a decrease in immunoreactivity to the full-length NR2B (Fig. 3.2A, n=3). At 
100 nM of thrombin, about 50 % of the full-length NR2B was cleaved (Fig. 3.2B). These 
observations demonstrated that thrombin can cleave NR2B in its native NMDA receptor 







Fig. 3.1. Characterization of cultured cortical neurons using immunofluorescence 
microscopy. (A) Double immunolabeling with neuronal and astrocyte marker. 
Photomicrograph showed significantly more βIII tubulin (Tub)-positive neurons (blue) than 
GFAP-positive astrocytes (green). (B-D) Photomicrographs showing immunolabeling of NR1 
(red), NR2B (green) and Tub (blue) in DIV11 cortical neuronal cells. (E) Merged 
immunofluorescence image showed co-localization of NR1 and NR2B in neurons (indicated 
by large arrowheads). (F) Photomicrographs showing NR1 (red) and NR2B (green) staining. 
Small arrow heads indicate clusters formed. The indicated segment of the image (white box) 
was magnified and showed in (G). (G) Both NR1 and NR2B subunits formed surface 
receptors and displayed as subunit cluster staining along dendrites (indicated by medium 




Fig. 3.2. Thrombin cleaves NR2B from NMDA receptor complex expressed on the 
membrane surface of cortical neurons. DIV11 cortical neurons were treated with thrombin 
for 2 h. (A) (Top panel) A 150 kDa fragment was detected with an C-terminal anti-NR2B 
upon 10 nM and higher concentrations of thrombin treatment (n=3). GAPDH was the loading 
control. Thrombin is indicated as Thr. Molecular weight (in kDa) of the protein and the 
fragments are as indicated. (B) Immunoreactivity quantification of full-length NR2B for the 
indicated treatment. Data (mean ± S.E.M.) were expressed in terms of percentage of initial 




Investigation of thrombin interaction with NR2B in the reducing environment experienced in 
ischemic stroke 
The above results demonstrated the possibility of thrombin cleavage of NR2B in its native 
conformation expressed in the NMDA receptor complex. Considering that ifenprodil binds to 
the ATD of NR2B, a change in the ifenprodil sensitivity can be an indicator of thrombin 
cleavage at the ATD of NR2B in functional receptors (Perin-Dureau et al., 2002a; Mony et 
al., 2009b). Thus, to further verify that thrombin cleaves NR2B in functional NMDA 
receptors, thrombin treatment was performed on NR2B subunit heterologously expressed with 
NR1 in Xenopus laevis oocytes. After which, ifenprodil inhibition was measured. Oocytes 
were treated to 400 nM thrombin for 20 min to allow maximal interaction between thrombin 
and NR2B without affecting viability of oocytes (Fig. 3.3A). The ifenprodil IC50 of 
NR1/NR2B was 0.21 ± 0.05 µM (n=26) in the absence of thrombin treatment (Fig. 3.3B). 
Thus three ifenprodil concentrations (0.1 μM, 1 μM and 10 μM) were chosen as they would 
be sufficient in detecting any significant rightward shift in the IC50 of ifenprodil if there was 
successful reduction in ifenprodil sensitivity induced by thrombin cleavage at the NR2B ATD 





Fig. 3.3. Basis for treatment conditions for proposed experimental paradigm. (A) 
Experimental paradigm: Open field indicates wash perfusion with recording solution. Gray 
field indicates 3 mM DTT treatment. Vertical stripped field indicates 400 nM thrombin 
treatment. Black field indicates glutamate and glycine treatment (100 µM each). Gradient 
gray field indicates the respective concentration of ifenprodil treatment in the presence of 
glutamate and glycine (100 µM each). GG indicates glutamate and glycine. Ifen indicates 
ifenprodil. Thr indicates thrombin. Time line (in min) is indicated at the bottom. (B-C) 
Responses were presented as percentages of currents measured against the maximum current 
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elicited by saturating concentration of glutamate and glycine on NR1/NR2B receptors. Each 
data point was the mean ± S.E.M., n=2-26 oocytes recorded. (B) Range of ifenprodil 
concentration to be used. Ifenprodil dose-dependent response curve for NR1/NR2B was 
plotted. Ifenprodil IC50 of 0.21 ± 0.05 µM, n=26 was indicated. 0.1 µM to 10 µM ifenprodil 
produced a sufficient range for detecting a rightward shift in ifenprodil sensitivity upon 
possible thrombin cleavage. (C) Time required for reverting the effects of DTT. Receptors 
were more potentiated upon longer DTT treatment (as color coded). All returned to the 
original state (100 % maximal response) upon wash out with recording buffer. The equation 
was the best-fit of the data points. The time for wash out for each DTT treatment were 





The probability of thrombin interaction with NR2B is the highest in pathological 
situations like stroke due to the increase in the level of thrombin during stroke condition 
(Karabiyikoglu et al., 2004; de Castro Ribeiro et al., 2006). In cerebral ischemic stroke, in 
addition to a change in the level of thrombin, the homeostatic environment is greatly 
disturbed. A reduction in oxygen in cerebral ischemic stroke would produce a reducing milieu 
in the affected brain area where proteolysis of NMDA receptors by thrombin could occur 
(Yager et al., 1991; Anderson et al., 1999; Chen and Shi, 2008). There are several redox sites 
at the NMDA receptors, which upon reduction, would result in potentiation of the NMDA 
receptors function through structural modification of the receptors via the disulfide bond at 
the redox sites (Table 1.1 in Chapter 1) (Tang and Aizenman, 1993; Sullivan et al., 1994; 
Brimecombe et al., 1999; Choi et al., 2001; Karakas et al., 2009). Thus I was interested in 
investigating whether such structural modification of the NMDA receptors during reducing 
condition would affect thrombin cleavage. I simulated the reducing environment by pre-
incubating oocytes in recording solution containing a reducing agent DTT (3 mM) for 3 min 
followed by 20 min of thrombin (400 nM) treatment (Fig. 3.3A). Thrombin activity in 3 mM 
DTT was not statistically different (6.5 x 10
-5




, n=6) compared to that in the 
absence of 3 mM DTT (6.2 x 10
-5




, n=6) (Fig. 3.4) (Serejskaya et al., 1983; 




Fig. 3.4. Thrombin activity is not altered by 3 mM DTT. Rate of hydrolysis of 
chromogenic substrates by thrombin in the absence or presence of 3 mM DTT were not 
statistically different from each other (indicated as n.s.) Statistical test used was paired T-test. 




In order to eliminate the concern that DTT affects the ifenprodil binding and as a 
consequence, affects the analysis of thrombin cleavage based on ifenprodil sensitivity, 
complete wash out of the DTT had to be carried out, allowing for the spontaneous reversal of 
the DTT effect (i.e. 100 % maximal response) (Tang and Aizenman, 1993). Ifenprodil 
sensitivity was measured only after the DTT effect was reverted (Fig. 3.3A and Fig. 3.3C). It 
was observed that 2 min of 4 mM DTT treatment required 3 min of wash out period for 
spontaneous reversal of the DTT effect. In our study, the oocytes were pretreated to 3 mM of 
DTT followed by 20 min of thrombin treatment under reducing condition. As such, the 
oocytes would be under a total of 23 min of DTT treatment (Fig. 3.3A). Thus it was 
investigated if longer treatment of DTT would require longer wash out period. Indeed, with 
increasing time of DTT treatment, a longer time was required to spontaneously reverse the 
DTT effect. This was due to the larger DTT potentiation effect observed with longer DTT 
treatment (Fig. 3.3C). Using the best fitted line-plots, time required to revert back to the 
original state for different time of DTT treatment was calculated. For 23 min of DTT 
treatment, 21.6 min wash out was required (Fig. 3.3B). Considering the data obtained and the 
variations in the NMDA responses, a wash out time of 24 min was set to ensure all NMDA 
receptors revert to original state before ifenprodil sensitivity was measured. As such, the 
experimental paradigm was as depicted in (Fig. 3.3A). Ifenprodil sensitivity was evaluated as 
the percentage of maximal response at three different ifenprodil concentrations (0.1 μM, 1 μM 
and 10 μM; gradient gray field in Fig. 3.3A) observed at steady-state on glutamate and 
glycine (100 μM each) evoked oocyte currents against glutamate and glycine treatment only 
(with no ifenprodil) after the washout.  
Thrombin-treated oocytes in the absence of reducing environment (-DTT) did not 
significantly decrease the ifenprodil (0.1 µM, 1 µM and 10 µM) sensitivity, an indication that 
NR2B may not be effectively cleaved under the specified experimental conditions (Table 
3.1). Interestingly, thrombin-treated oocytes (in 3 mM DTT) shifted the ifenprodil 
concentration-response curve to the right as compared to no thrombin treatment (Fig. 3.5A). 
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This observation indicated that thrombin treatment had reduced the inhibitory effect of 
ifenprodil on the NR1/NR2B receptors. At 0.1 μM of ifenprodil, agonists-evoked response 
was significantly higher in thrombin (+DTT) group (54.8 ± 2.96 %, n=13 oocytes) as 
compared to no thrombin (+DTT) group (41.2 ± 3.87 %, n=12; P < 0.05; one-way ANOVA, 
post-hoc Tukey test), thrombin (-DTT) group (35.1 ± 6.13 %, n=6; P < 0.01; one-way 
ANOVA, post-hoc Tukey test) and no thrombin (-DTT) group (34.2 ± 2.46 %, n=7; P < 0.01; 
one-way ANOVA, post-hoc Tukey test) (Fig. 3.5B and Table 3.1). At 1 μM and 10 μM of 
ifenprodil, there was a trend of increase in the agonist-evoked responses in thrombin (+DTT) 
treatment group as compared to other treatment groups (Table 3.1). The shift in ifenprodil 
sensitivity was due to thrombin cleavage and was not contributed by DTT affecting ifenprodil 
binding as ifenprodil inhibition was not statistically different for oocytes treated with +DTT/-
thrombin compared to –DTT/-thrombin treatment (Table 3.1). These results described, 





Table 3.1. Thrombin treatment alters NR1/NR2B receptors ifenprodil inhibition under 
reducing condition but not in non-reducing condition. Ifenprodil sensitivity was not 
statistically different between with and without thrombin treatment in the absence of DTT at 
the three concentration of ifenprodil (0.1, 1 and 10 µM ifenprodil) tested. * and ** 
represented P < 0.05 and P < 0.01 respectively when compared to thrombin treatment in the 
presence of 3 mM DTT. Statistical test used was one-way ANOVA, post-hoc Tukey test. n 




Fig. 3.5. Thrombin decreases ifenprodil inhibition of recombinant NR1/NR2B receptors 
but not NR1/NR2B(K318A) receptors under reducing condition. (A) % maximal 
responses produced by 0.1 μM, 1 μM and 10 μM of ifenprodil after -/+ thrombin (Thr) 
treatment in the presence of 3 mM DTT on NR1/NR2B receptors and (C) on 
NR1/NR2B(K318A) receptors.  indicates +DTT/-Thr treatment.  indicates +DTT/+Thr 
treatment. (B) % maximal responses in the presence of 0.1 μM of ifenprodil under four 
different treatment conditions depicted in Fig. 3.3A for NR1/NR2B and (D) for 
NR1/NR2B(K318A).  indicates value obtained from each experiment. * and ** represent P 
< 0.05 and P < 0.01, respectively. n.s. indicates that results were not statistically different. 
Statistical test used was one-way ANOVA, post-hoc Tukey test. n=4-13 oocytes recorded (in 




To further confirm the hypothesis that the relief of ifenprodil inhibition observed in 
Fig. 3.5A was due to thrombin cleavage at Lys
318
 on the NR2B ATD, Lys
318
 was mutated to 
alanine (NR2B(K318A)). Ifenprodil inhibition was then measured from NR1/NR2B(K318A)-
expressing oocytes in the same manner (±thrombin/±DTT) as described earlier for oocytes 
expressing heterologous NR1/NR2B receptors. Consistent with the hypothesis, we found that 
there was no rightward shift in the ifenprodil concentration-response curves (Fig. 3.5C) unlike 
that observed in thrombin treatment (+DTT) on wild-type NR1/NR2B (Fig. 3.5A). At 0.1 μM 
ifenprodil, the agonist-evoked response for thrombin treated under reducing condition (49.0 ± 
2.33 %, n=6) was similar to that in the absence of thrombin under reducing condition (45.3 ± 
8.43 %, n=5; P > 0.05; one-way ANOVA, post-hoc Tukey test) (Fig. 3.5D and Table 3.2). 
Taken together, these data suggest that thrombin-induced removal of ifenprodil inhibition of 






Table 3.2. Thrombin treatment under reducing condition does not alter 
NR1/NR2B(K318A) receptors ifenprodil sensitivity. Ifenprodil sensitivity for the different 
treatment groups were not significantly different from each other at the ifenprodil 
concentration (0.1, 1 and 10 µM) tested. Statistical test used was one-way ANOVA, post-hoc 
Tukey test. n indicates the number of oocytes tested. Values represented mean ± S.E.M.  
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3.4 Discussion  
The present study demonstrated that nanomolar concentration of thrombin can moderate 
NR2B-containing NMDA receptor’s sensitivity to ifenprodil, at least in part in a reducing 
environment, by cleaving NR2B ATD at Lys
318
. Importantly, if NR2B-selective antagonists 
targeted at the ATD were to be administered to reduce excitotoxicity, the efficacy of such 
drugs may be reduced by thrombin’s proteolytic cleavage of NR2B at the ATD. Thus, the 
findings from this study hold implications for the design of new drug leads that are negative 
allosteric modulators of NMDA receptors binding at the ATD.  
 
Structural implications of thrombin cleavage on NR2B 
It is demonstrated that thrombin cleaved NR2B in a reducing environment but not in the non-
reduced state (Fig. 3.5). Examining the crystal structure of the NR2B ATD (3JPW) that has 
recently been published, Lys
318
 is located approximately to the centre of a hypervariable loop 
(HVL) and is lying right above helix 1 and helix 2 (Fig. 3.6) (Karakas et al., 2009). The HVL 
of the ATD is made up of 18 amino acids and links helix 8 to helix 9. The HVL appears to be 
rigid as held by a disulfide bond formed between Cys
86
 on helix 1 and Cys
321
 on the HVL 
loop. The intraprotomer disulfide bond orientates the HVL in a way such that the loop 
appears to be a “lid” covering the R1 domain and renders Lys318 not as solvent accessible in 
the native conformation (Fig. 3.6A). This could also be the reason for the less efficient 
cleavage or an absence of cleavage under non-reducing conditions (Table 3.1, Fig. 3.5A and 
Fig. 3.5B). Since both apo- and Zn
2+
-bound conformations (3JPW and 3JPY respectively) are 
similar to each other with root mean square (r.m.s.) deviation of only 0.56 Å over 356 Cα 
positions, we expect Lys
318
 to be relatively inaccessible to thrombin in both conformations 




Fig. 3.6. Crystal structure of apo-NR2B ATD and location of Lys
318
. (A) Ribbon 
representation of the apo-NR2B ATD structure (3JPW) generated using Protein Workshop. 
Secondary structures are as labeled (Karakas et al., 2009). N-terminal is indicated as NT 
while C-terminal is indicated as CT. The clam-shell structure of the NR2B ATD is made up 
of two domains, R1 (blue) and R2 (magenta). The disordered region (residues 208-214) is 










involved in ifenprodil 
inhibition are colored green. The disulfide bond formed between Cys
86
 (blue) and Cys
321
 
(orange) is highlighted as a pale orange dotted line. The disulfide bond is involved in holding 
the HVL (orange) in place such that the HVL covers the top of R1. Lys
318
 (yellow) lies on 
HVL. (B) Zoom in view of the spatial orientation of Lys
318
 on the HVL with respect to the 
disulfide bond. (C) NR2B ATD structure viewed from the front of the HVL. Reducing 




, affecting the 
intact structure of the HVL.  
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In ischemic stroke, many proteins are in a reduced state (Anderson et al., 1999; Chen 









 to the 
respective thiol groups may render the HVL more flexible and may cause the Lys
318
 residue to 
be more solvent accessible (Fig. 3.6B and Fig. 3.6C). This hypothesis was further 
demonstrated through a molecular dynamics simulation carried out by our collaborator, Dr 




, it was 
shown in the molecular model that the Lys
318
 becomes exposed to the extracellular milieu 
(Fig. 3.7). Moreover, in the present study, it was also observed that point mutation at K318A 
was able to block the proteolytic effects of thrombin, which further supported the notion that 
thrombin could access the cleavage site (Lys
318
) on NR2B ATD under reducing condition 




 residues are highly conserved among NR1 and 
NR2 subunits (Fig. 3.8). From the structure, we envisaged that under reducing condition, the 
reduction of the disulfide bond would allow more flexibility at the HVL and cleavage of the 
HVL of the NR1 and the other NR2 subunits could concur in a similar way (Fig. 3.6C). 
However, due to the absence of molecular recognition motif in all other subunits, thrombin 
cleavage is less likely (Fig. 3.8) (also briefly discussed in Chapter 2) (Gingrich et al., 2000). 
However, HVL may, nevertheless, be prone to other proteases cleavage that has different 
molecular recognition motif from thrombin (Fig. 3.8) (Samson et al., 2008; Yuan et al., 
2009b). Thus, the disulfide bond acts as a redox switch and plays a crucial role in determining 
the accessibility of residues like Lys
318 
on NR2B to proteases like thrombin (Lipton et al., 




Fig. 3.7. Molecular dynamics simulation based on the NR2B ATD crystal structure 
(3JPY). The dynamics simulation and post-progressing sampling were carried out using the 
Amber10 program package. The dynamics simulation spanned over a period of 10 ns and 
snapshots of the conformation of the protein were sampled every 500 ps throughout the whole 
dynamic process. All the snapshots (in PDB format) were then superimposed onto and 
compared with the NR2B crystal structure (3JPY). Pictures of each conformation were taken 
and saved separately with Accelrys Discovery Studio. The first frame and the last frame of 
the simulation are presented here. Lys
318
 (yellow) in NR2B protein was minimized prior to the 
production run to reduce any possible clashes among the amino acids. Molecular simulation 





 (indicated as orange dotted line) during reducing condition. Lys
318
, located at the 
HVL (as indicated), was shown to be exposed to the extracellular milieu upon reduction of 
the disulfide bond. The R1 domain, R2 domain and the secondary structures are as labeled 





Fig. 3.8. NR1 and NR2 ATD sequence alignment. The ATD of NR2B, human NR2B 
(hNR2B), the different NR2 subunits (NR2A-D) and NR1 protein sequences are aligned using 
ClustalW (http://www.ebi.ac.uk/Tools/clustalw2/index.html). The cysteine residues that are 





 is highlighted in light purple. The P1 Pro
317
 is highlighted in light blue. 
The P1’ Ser319 is highlighted in light brown. Plasmin cleavage sites are highlighted in cyan. 
tPA cleavage site is highlighted in orange. Residues that are important for binding to 
ifenprodil are highlighted in green. Conserved residues of the above mentioned sites are 
boxed up in their respective color. * indicates residues are conserved. : indicates conserved 
substitution. . indicates semi-conserved substitution. Secondary structures of NR2B ATD are 
indicated as blue arrows for β-strands and black boxes for α- and η(310)-helices (Karakas et al., 






Functional implications of thrombin cleavage on NR2B 
The oocyte functional data showed significant decrease in ifenprodil inhibition at 0.1 µM but 
not 1 µM and 10 µM ifenprodil upon thrombin treatment in the presence of 3 mM DTT. We 
proposed that at 400 nM thrombin (20 min treatment in the presence of 3 mM DTT), the 
proportion of cleaved NR2B is at a low level. As concentrations of ifenprodil increases (1 µM 
and 10 µM in this study), the probability of ifenprodil molecules binding to the uncleaved 
NR2B increases. The resultant degree of inhibition by high concentrations of ifenprodil would 
resemble that of wild-type NR1/NR2B receptors and hence would not show significant 
difference between the cleaved and intact NR1/N2B receptors. Increasing the time of 
exposure and concentration of thrombin would likely cause more disruption in the ATD via 
cleavage and possibly a greater change in the ifenprodil inhibition (i.e. even at higher 
concentration of 1 µM and 10 µM ifenprodil). Unfortunately, from my experience, increasing 
time (up to 40min) and concentration (up to 500 nM) of thrombin treatment rendered oocytes 
unstable to prolonged TEVC recordings. Thus, it would be interesting to investigate how full 
cleavage of NR2B Lys
318
 affects the function of the NMDA receptors.  
 
Clinical implications of thrombin cleavage on NR2B 
It is shown in this study that 400 nM of thrombin can cleave Lys
318
 under reducing condition, 
one of the pathological conditions present in ischemic stroke. Cleavage at the Lys
318
 lowered 
the ifenprodil inhibition on NMDA receptors. Ifenprodil and their analogues had been 
investigated as potential drug leads in ischemic stroke. However, such clinical trials have 
failed due to adverse effects or absence of positive stroke outcome (Nikam and Meltzer, 2002; 
Gogas, 2006). One of the reasons for the lack of translational success from animal stroke 
models lies in the way such stroke models are conducted. Unlike typical stroke patients who 
are usually old and may suffer from other health complications, young and healthy rodents are 
used as subjects of stroke model. The typical animal ischemic stroke model, MCAO, does not 
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involve the formation of a blood clot to mimic ischemic stroke (Ginsberg, 1996; Hoyte et al., 
2004; Fisher and Tatlisumak, 2005). Choosing the right method for inducing an ischemic 
stroke model in animal clinical trials is crucial considering a 50-μl clot, a typical inducer for 
ischemic stroke,  produces 15 U thrombin per ml of plasma (150 nM of thrombin) (Seegers, 
1962; Arand and Sawaya, 1986; Lee et al., 1996; Gingrich and Traynelis, 2000). Thus when 
the blood brain barrier becomes compromised during ischemic stroke, large quantity of 
thrombin may extravasate into the brain parenchyma to cleave NR2B. In the reducing 
condition of the ischemic stroke, cleavage at Lys
318
 renders NR2B less ifenprodil sensitive 
(Fig. 3.5). This may also be one of the reasons NR2B ATD binding drugs, e.g. ifenprodil and 
its analogues, have improved the outcome of MCAO animal stroke models but fail in 
improving that in stroke patients (Gotti et al., 1988; Di et al., 1997; Ikonomidou and Turski, 
2002; Gogas, 2006). Considering the results on the cleavage of NR2B and also the recent data 
on other proteases cleaving the NMDA receptors, such cleavage of NMDA receptors can 
modulate sites of interaction with drug leads (Fig. 3.8) (Nicole et al., 2001; Fernandez-
Monreal et al., 2004; Pauly et al., 2008; Samson et al., 2008; Szklarczyk et al., 2008; Yuan et 












Functional effects of thrombin cleavage  
on NR2B-containing receptors 
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4 Functional effects of thrombin cleavage on NR2B-containing receptors 
4.1 Background and objectives 
In Chapter 3, it was shown that thrombin can cleave NR2B in its native conformation. 
Two possible scenarios could be foreseen upon thrombin cleavage (Fig. 4.1). (1) Upon 
thrombin cleavage at Lys
318
 of NR2B ATD, the cleaved fragment up to residue Lys
318
 might 
be loosely associated to the rest of the receptors by Van der Waals forces and hydrogen bonds 
formed among the α-helices and β-sheets. There is disruption to the ATD but to a smaller 
extent compared to the second scenario. (2) The other possible scenario could be the complete 
dissociation of the fragment up to residue Lys
318
 from the NMDA receptor complex upon 
treatment by thrombin. In this study, we will investigate the effects of both scenarios on the 




Fig. 4.1. Model illustrating two possible scenarios upon thrombin cleavage at Lys
318
 of 
NR2B based on the NR2B ATD crystal structure (3JPW). Ribbon representation of the 
apo-NR2B ATD structure (3JPW) generated using Protein Workshop. (Top panel) NR2B 
ATD structure illustrates the state of NR2B ATD before thrombin cleavage. Secondary 
structures are as labeled (Karakas et al., 2009). NT indicates N-terminal while CT indicates C-
terminal. R1 and R2 domain are colored in blue and magenta respectively. The HVL (orange) 
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 (orange) and covers the top of R1. The disordered region (residues 208-214) is 
indicated as a dotted line. The respective positions of K318 and S319 are as indicated and 











) are indicated in green. Upon thrombin cleavage, two 
scenarios are hypothesized. (Left, bottom panel) Scenario 1 is shown in which there is 
minimal change in the overall structure. Black color indicates the bond between K318 and 
S319 where thrombin proteolyze at. Cleavage at Lys
318
 may induce changes in the structure of 




, affecting its ability to form 
disulfide bond (further illustrated in Fig. 4.2). (Right, bottom panel) Scenario 2 is shown in 
which the ATD region up to Lys
318
 is completely removed.  
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In scenario one where the cleaved fragment is loosely attached to the rest of the 





 (Fig. 4.2). Formation of disulfide bonds requires a minimum 
distance of 6.4 Å and an angle of ~115° between the side chains of two cysteine residues. 
Formation of the disulfide bond also takes into consideration that water molecule cannot pass 
between them owing to excluded volume (Colonna-Cesari and Sander, 1990; Dombkowski 
and Crippen, 2000; Seeger et al., 2008). The disulfide bonds between the various cysteine 
pairs in the NMDA receptors may maintain important structural configuration that is crucial 
for governing the sensitivity of the receptors to modulators and to agonists (Table 1.1 in 
Chapter 1) (Tang and Aizenman, 1993; Sullivan et al., 1994; Gozlan and Ben-Ari, 1995; Choi 
et al., 2001; Kaye et al., 2007; Karakas et al., 2009). Thus, one of the objectives of the study 
is to utilize substitution mutants to investigate how a failure in forming the intraprotomer 




 would affect the function of NMDA receptors. As 
the ATD is involved in binding to the modulator ifenprodil, the sensitivity to ifenprodil would 
be investigated (Perin-Dureau et al., 2002a; Mony et al., 2009b). It is also evident that the 
ATD modulates the action of the LBD, thus, the sensitivity to the agonist glutamate and co-





Fig. 4.2. Enlarged representation of scenario 1. Upon thrombin cleavage under reducing 
condition at K318 (yellow residue), the peptide bond (pale yellow) between K318 and S319 
(red) is cleaved, leaving a broken HVL (orange). The disrupted HVL structure may increase 




 indicated by the double-
headed arrows. Secondary structures are as indicated (Karakas et al., 2009). Figure is 




In scenario two, the functional consequences in the situation when the portion of the 
ATD region up to Lys
318
 is removed would be determined. In addition to the importance of 
binding to modulators such as ifenprodil, the ATD of NR2 subunits are also important in 
allosterically modulating the binding of agonists at the LBD (Zheng et al., 2001; Perin-
Dureau et al., 2002a; Madry et al., 2007a; Mony et al., 2009b). Recently, it is also observed 
that the ATD is important for the modulation of channel kinetics (Gielen et al., 2009; Yuan et 
al., 2009a). Thus in this study, we would like to investigate how the removal of a big portion 
of the ATD (up to Lys
318
), as in the case upon cleavage at Lys
318
, would affect the properties 
of the NMDA receptors. 




4.2 Materials and methods 
pCIneo NR1-1a and pcDNA1 NR2B were gifts from Dr. S.F. Heinemann. pCIneo 
NR2B(C86A), pCIneo NR2B(C321A), pCIneo NR2B(C86A/C321A) double cysteine mutant 
and pCIneo NR2B(C232A) were constructed by F.M. Ng from our laboratory. pcDNA1 
NR2B-ΔATD-K318 was constructed by J.T. Chen, N. Anthony and Y. Zhang from our 
laboratory. SP6 NR1-1a(A652C) was a gift from Dr. S.F. Traynelis. Restriction enzymes, 
QIAquick gel extraction kit, mMESSAGE mMACHINE T7 kit, RNA ladder, Xenopus laevis 
frogs, PMSF, pepstatin A, leupeptin hemisulfate, protein marker, ECL Plus, glutamate, 
glycine and ifenprodil were purchased from companies as described in Chapter 3. 
mMESSAGE mMACHINE SP6 kit was purchased from Ambion (Austin, TX, USA). Anti-
NR1 mouse monoclonal antibody (recognizing the amino acids 660-881 of rat NR1) was 
purchased from BD Pharmingen (San Diego, CA, USA). C-terminal anti-NR2B rabbit 
polyclonal antibody (recognizing amino acid residues 1437-1456 of mature mouse NR2B) 
was purchased from Upstate Biotechnology (Lake Placid, NY, USA). For secondary 
antibodies, both the goat anti-rabbit and goat anti-mouse IgG horseradish peroxidase 
antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). D-
cycloserine was purchased from Sigma (St Louis, MO, USA). 2-aminoethyl 
methanethiosulfonate hydrobromide (MTSEA) was purchased from Toronto Research 
Chemicals (Ontario, Canada). All chemicals were purchased from Sigma-Aldrich (St Louis, 
MO. USA).  
 
Harvesting Xenopus laevis oocytes 
Stage V/VI oocytes were obtained from the ovaries of Xenopus laevis frogs and maintained in 





Expression of NR1/NR2 receptors in Xenopus oocyte injection 
pCIneo NR1-1a, pcDNA1 NR2B, pCIneo NR2B(C86A), pCIneo NR2B(C321A), pCIneo 
NR2B(C86A/C321A), pCIneo NR2B(C232A) and pcDNA1 NR2B-ΔATD-K318 were 
linearized using NotI. SP6 NR1-1a(A652C) was linearized using MluI. Linearized DNA were 
analyzed and purified as described in Chapter 3. With the exception of SP6 NR1-1a(A652C), 
all RNA were generated from their respective linearized DNA using mMESSAGE 
mMACHINE T7 kit according to the manufacturer’s protocol. SP6 NR1-1a(A652C) RNA 
was generated from the linearized DNA using mMESSAGE mMACHINE SP6 kit. Quality of 
RNA was analyzed using analytical 0.6 % agarose gel electrophoresis and quantity was 
measured using ND-1000 spectrophotometer (NanoDrop Technologies, Montchanin, DE, 
USA). Oocytes were injected under the magnification of SMZ435 dissecting scope (Nikon, 
Tokyo, Japan) after 24 h of isolation. Oocytes were injected with 10-25 ng of RNA in a 50 nl 
volume using oocyte microinjection pipet (Drummond Scientific, Broomall, PA, USA) 
mounted on a Marzhauser MM33 micromanipulator (SDR, Sydney, Australia). The ratio of 
NR1 to NR2 was at 3:7. Following injection, oocytes were incubated at 17C in Barth’s 
solution.  
 
Homogenization of oocytes 
At 3-8 days after RNA injection, total protein was obtained by lyzing 20 oocytes in 400 µl of 
homogenization buffer (100 mM NaCl, 1 % Triton X-100, 20 mM Tris-HCl, pH 7.4) in the 
presence of protease inhibitors (1 mM PMSF, 1.5 µM pepstatin A and 4.4 µM leupeptin 
hemisulfate). The homogenate was then centrifuged at 14000 g for 1 min. Supernatant was 





Measurement of protein concentration  
Measurement of protein concentration of oocyte homogenate was performed using BCA 
protein assay as described in Chapter 2. BSA standard was reconstituted in homogenization 
buffer. Absorbance was measured at 562 nm.  
 
SDS-PAGE and immunoblotting  
The proteins were separated by SDS-PAGE and analyzed by immunoblotting as described in 
Chapter 2. Immunoblotting was performed using C-terminal anti-NR2B (1 : 800) or anti-NR1 
(1 : 2000). Detection of primary antibodies was performed using anti-rabbit IgG horseradish 
(1 : 20000) or anti-mouse IgG horseradish peroxidase (1 : 5000) followed by ECL Plus.  
 
TEVC recordings from Xenopus oocytes 
Recordings were performed as described in Chapter 3. Saturating concentration of glutamate 
and glycine (30-100 µM) and 0.03-10 µM of ifenprodil or 0.01-1000 µM of D-cycloserine 
were used in all oocytes experiments unless otherwise stated. Glutamate (50 μM), glycine (30 
μM) and 0.2 mM MTSEA were used to investigate the POPEN of receptors. MTSEA was 
prepared fresh and used within 20 min. Data points were collected from at least two different 
Xenopus laevis frogs. 
 For the antagonist ifenprodil, experimental points were fitted with the following 
equation for:  
Percent response = (100 – minimum) / (1 + ([ifenprodil]/IC50)
n
) + minimum 
obtaining the ifenprodil inhibition curves, where minimum is a residual current response, IC50 
is the concentration of ifenprodil that produces 50 % of the maximal inhibition and n is the 
Hill slope.  
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For the agonist (glutamate), co-agonist (glycine) and partial agonist (D-cycloserine), 
data points were fitted to the following equation: 
 Percent response = 100 x relative efficacy / (1 + (EC50/[agonist])
n
)  
obtaining the full agonist curves where relative efficacy is the response at maximally effective 
concentration relative to the maximal response of glutamate or glycine (as indicated in the 
respective experiment), EC50 is the concentration of agonist that produces 50% maximum 
activation and n is the Hill slope. 
 
Illustration of crystal structure of NR2B ATD 
The apo-crystal structure of NR2B ATD (Protein Data Bank code 3JPW) provided the 
structural template to create the images using Protein Workshop (Karakas et al., 2009).  
 
Data analysis 
Data were expressed as mean ± S.E.M. and analyzed statistically using unpaired T-test or 
one-way ANOVA followed by Dunnett test. Significance for all tests was set at P < 0.05. 
Error bars in figures were S.E.M. Graphs were plotted using GraphPad PRISM® Version 4.  
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4.3 Results  




 affects the function of 
NMDA receptors minimally 
The cleavage at Lys
318
 observed suggested two possible scenarios. One of which could be the 




 due to the increase in distance 
introduced by the cleavage at Lys
318
 at the HVL of ATD NR2B (Fig. 4.2). Using 
NR2B(C86A), NR2B(C321A) and NR2B(C86A/C321A) double cysteine mutants, we 
investigated how the absence of the disulfide bond affect the function of the NMDA 
receptors. NR2B(C232A) was also included as a form of control in the investigation as it is 
the only other cysteine in the ATD and it is not involved in the formation of the disulfide 
bond (Karakas et al., 2009). Considering that the ATD is directly involved in the binding of 
ifenprodil, the IC50 of ifenprodil was measured. The IC50 of ifenprodil were not significantly 
altered among the cysteine mutants compared to the wild-type (Table 4.1). The IC50 ranged 
from 0.07 to 0.17 µM, i.e. close to the IC50 of wild-type NR1/NR2B (0.21 ± 0.05 µM, n=26; 
P > 0.05; one-way ANOVA, post-hoc Dunnett test) (Table 4.1). The sensitivities of these 
cysteine mutants to the agonist glutamate and co-agonist glycine were also investigated. The 
glutamate EC50 and glycine EC50 were not significantly changed among the wild-type and 
cysteine mutants (Table 4.1). For the glutamate EC50, it ranged from 0.54 to 1.75 µM and that 
for glycine ranged from 0.25 to 0.39 µM for the cysteine mutants tested (Table 4.1). These 
values were similar to those of the wild-type NR1/NR2B glutamate EC50 (1.28 ± 0.19 µM, 
n=19; P > 0.05; one-way ANOVA, post-hoc Dunnett test) and glycine EC50 (0.29 ± 0.03 µM, 
n=20; P > 0.05; one-way ANOVA, post-hoc Dunnett test). These indicated that the failure in 
forming the disulfide bond (possibly induced by thrombin cleavage) does not affect the 





 did not cause a major change in the structure of the NMDA receptors and did not 




Table 4.1. Ifenprodil IC50, glutamate EC50 and glycine EC50 are not altered in NR2B 
ATD cysteine mutants. IC50 of ifenprodil were obtained by co-application of 0.03-10 µM of 
ifenprodil in the presence of 30-100 µM glutamate and glycine. Glutamate and glycine EC50 
were determined in the presence of saturating glycine or glutamate respectively (30-100 µM). 
Ifenprodil IC50, glutamate EC50 and glycine EC50 of cysteine mutants were not significantly 
altered as compared to wild-type NR1/NR2B. Statistical test used was one-way ANOVA, 





Deletion of NR2BATD at Lys
318
 is functional but ifenprodil-insensitive in oocytes 
Thrombin cleavage at Lys
318
 also raised the possibility that a population of NMDA receptors 
may exist where the ATD of NR2B is truncated at Lys
318
 after coming into contact with 
thrombin and this receptor species is functional but resistant to ifenprodil inhibition (scenario 
two) (Fig. 4.1). To evaluate if there are functional changes of these receptors, a NR2B DNA 
plasmid with the NR2B ATD up to Lys
318
 deleted (NR2B-ATD-K318) was generated. This 









sequentially using QuikChange site directed mutagenesis on pcDNA1 NR2B wild-type 
plasmid template as previously reported in (Yuan et al., 2009b) (Fig. 4.3A). This NR2B-
ATD-K318 was co-expressed with wild-type NR1 in oocytes (Fig. 4.3B).  Dose-response 
curves for ifenprodil (0.03-10 µM) inhibition were generated from recombinant wild-type 
NR1/NR2B and NR1/NR2B-ATD-K318 receptors expressed in oocytes in the presence of a 
saturating concentration of glutamate and glycine. The high affinity ifenprodil inhibition was 
significantly reduced in NR1/NR2B-ATD-K318 receptors (estimated IC50 > 100 M, n=4) 
(Fig. 4.4B, Fig. 4.4C and Table 4.2) as compared to wild-type receptors (IC50 0.21 ± 0.05 M, 
n=26) (Fig. 4.4A, Fig. 4.4C and Table 4.2). Coincidentally, all known critical residues that 
exert major influence on ifenprodil- and benzimidazole derivative-mediated inhibitions of 










, are located upstream 
from the thrombin cleavage site Lys
318
 on NR2B ATD (Fig. 4.1 top and bottom right panel) 
(Perin-Dureau et al., 2002b; Mony et al., 2009c; Wee et al., 2010). This explained the relief of 




Fig. 4.3. Construction and expression of the truncated mutant NR2B-ATD-K318. (A) 
Schematic diagram showing the construction of NR2B-ATD-K318 from the wild-type 




. This construct included the first 28 residues of 
NR2B which are the signal peptides. Gray rectangular box indicates the linker between ATD 
and S1. Black rectangular boxes indicate the transmembrane domain (M1, M3 and M4) and 
the re-entrant loop (M2). Domains are as indicated.  (B) NR2B-ΔATD-K318 DNA translated 
into a ~150 kDa truncated NR2B subunit when co-expressed with NR1 in Xenopus oocytes. 
Homogenate of NR1/NR2B or NR1/NR2B-ΔATD-K318 injected oocytes were analyzed on 




Fig. 4.4. NR2B-ΔATD-K318 abolishes high-affinity ifenprodil inhibition. Representative 
current traces recorded from Xenopus oocytes co-expressing rat (A) NR1/NR2B and (B) 
NR1/NR2B-ATD-K318 upon ifenprodil (Ifen) and saturating glutamate (Glu) and glycine 
(Gly) treatment. The horizontal short lines show applications of 0.03, 0.1, 0.3, 1, 3 and 10 µM 
ifenprodil. (C) Dose-dependent inhibition curves for ifenprodil. Maximal response (%) 
represented the percentage of current measured at each ifenprodil concentration tested to the 
maximum current elicited by saturating concentration of glutamate and glycine.  indicates 
NR1/NR2B-injected oocytes.  indicates NR1/NR2B-ΔATD-K318-injected oocytes. Each 




NR2B-ΔATD-K318 affects glycine but not glutamate EC50 
As the ATD can allosterically modulate the function of LBD, the truncated mutant NR2B-
ΔATD-K318 was also employed to investigate the effects of removing region of the ATD up 
to Lys
318
 on the glutamate and glycine EC50 values, which are ligands binding to the LBD of 
NR2 and NR1 respectively (Zheng et al., 2001; Gielen et al., 2008). Here, we assumed that 
glycine and glutamate are full agonists and produce maximal receptor activation. The EC50 of 
glutamate measured in the presence of saturating concentration of glycine on NR1/NR2B-
ATD-K318 receptors (1.12 ± 0.09 M, n=6) (Fig. 4.5B, Fig. 4.5C and Table 4.2) was 
similar to that of wild-type NR1/NR2B (1.28 ± 0.19 M, n=19; P > 0.05; unpaired T-test) 
(Fig. 4.5A, Fig. 4.5C and Table 4.2). The NR1/NR2B-ΔATD-K318 receptor EC50 for glycine 
was, however, significantly higher by 14-fold (4.27 ± 0.50 M, n=5) (Fig. 4.6B, Fig. 4.6C 
and Table 4.2) as compared to NR1/NR2B (0.29 ± 0.03 M, n=20; P < 0.0001; unpaired T-




Fig. 4.5. NR2B-ΔATD-K318 does not alter glutamate EC50. Representative current traces 
recorded from Xenopus oocytes co-expressing rat (A) NR1/NR2B and (B) NR1/NR2B-
ATD-K318 upon glutamate (Glu) and saturating glycine (Gly) treatment. The horizontal 
short lines show applications of 0.1, 0.3 1, 3, 10, 30 and 100 µM glutamate. (C) Dose-
dependent activation curves for glutamate. Maximal response (%) represented the percentage 
of current measured at each glutamate concentration tested to the maximum current elicited 
by saturating concentration of glycine.  indicates NR1/NR2B-injected oocytes.  indicates 
NR1/NR2B-ΔATD-K318-injected oocytes. Each data point was the mean ± S.E.M., n=6-19 




Fig. 4.6. NR2B-ATD-K318 reduces glycine EC50 significantly (P < 0.0001). 
Representative current traces recorded from Xenopus oocytes co-expressing rat (A) 
NR1/NR2B and (B) NR1/NR2B-ATD-K318 upon glycine (Gly) and saturating glutamate 
(Glu) treatment. The horizontal short lines show applications of 0.1, 0.3, 1, 3, 10, 30 or 100 
µM glutamate. (C) Dose-dependent activation curves for glycine. Maximal response (%) 
represented the percentage of current measured at each glycine concentration tested to the 
maximum current elicited by saturating concentration of glutamate.  indicates NR1/NR2B-
injected oocytes.  indicates NR1/NR2B-ΔATD-K318-injected oocytes. Each data point was 




NR2B-ΔATD-K318 changes partial agonist efficacy 
Co-agonist glycine binds to the NR1 LBD of the NMDA receptors. Interestingly, removal of 
the ATD region up to Lys
318
 of the NR2B subunit caused a change in the EC50 of glycine (Fig. 
4.6). Thus it was hypothesized the binding of NR1 partial agonist could be affected. Although 
the NR1/NR2B-ATD-K318 receptors only yielded a small EC50 reduction for D-cycloserine 
(EC50 3.86 ± 0.81 M, n=10) (Fig. 4.7B, Fig. 4.7C and Table 4.2) as compared to the wild-
type receptors (EC50 4.83 ± 0.98 M, n=7; P > 0.05; unpaired T-test) (Fig. 4.7A, Fig. 4.7C 
and Table 4.2), the relative efficacy of D-cycloserine was increased from 44.3 to ± 3.95 % 
(n=7) of glycine in NR1/NR2B receptors (Fig. 4.7A and Fig. 4.7C) to 83.4 ± 4.90 % (n=10) in 
NR1/NR2B-ATD-K318 receptors (Fig. 4.7B and Fig. 4.7C) (P < 0.0001; unpaired T-test). 
These results suggested that the ATD may be involved in regulating co-agonist binding site 
and that there may be multiple factors responsible for the differences in D-cycloserine and 




Fig. 4.7. NR2B-ATD-K318 increases partial agonist D-cycloserine efficacy (Emax) (P < 
0.0001). Representative current traces recorded from Xenopus oocytes co-expressing rat (A) 
NR1/NR2B and (B) NR1/NR2B-ATD-K318. 0.01, 0.1, 1, 10, 100 or 1000 µM D-
cycloserine (DCS) (represented by horizontal short lines) was co-applied with 100 µM 
glutamate (Glu). Relative efficacy of D-cycloserine was compared to saturating concentration 
of glutamate and glycine (Gly). (C) Dose-dependent activation curves for DCS. % of response 
induced by D-cycloserine was normalized as a percentage of the maximal response obtained 
at saturating glycine and glutamate.  indicates NR1/NR2B-injected oocytes.  indicates 
NR1/NR2B-ΔATD-K318-injected oocytes. Each data point was the mean ± S.E.M., n= 7-10 





Table 4.2. NR2B-ATD-K318 alters the glycine EC50 and ifenprodil IC50 but not 
glutamate EC50 and D-cycloserine EC50 of NMDA receptors. The IC50 value for the 
ifenprodil binding on NR1/NR2B-ATD-K318 was estimated from the plot. There was a 
significant increase in the glycine EC50 between wild type and NR2B-ATD-K318. * 
represents P < 0.0001. Statistical test used was unpaired T-test. n=4-26 oocytes recorded (in 




Deletion of NR2B ATD does not alter NR1/NR2B channel POPEN 
The ATD of NR2B binds to ifenprodil resulting in the closure of the ATD cleft (Perin-Dureau 
et al., 2002a; Mony et al., 2009b). This in turn leads to receptor inhibition through interaction 
with the LBD interface (Gielen et al., 2008). In short, the ATD has two conformations, a 
ligand-free open state of the receptors and a ligand-bound close state of the receptors 
(Karakas et al., 2009) (Fig. 4.9 top panel). Thus it was hypothesized that the removal of ATD 
region up to Lys
318
 could play a role in modulating the channel opening. We investigated the 
channel POPEN of the NR2B-ΔATD-K318-containing receptors as POPEN is one of fundamental 
differences among the NR2 subtypes (Chen et al., 1999; Erreger et al., 2005). We estimated 
POPEN using a method based on the covalent modification by the thiol-modifying reagent 
(MTSEA) on a cysteine introduced in the NR1 subunit (NR1(A652C)). This residue is one of 
the residues of the highly conserved motif (SYTANLAAF) located at the M3 of the NR1. 
Upon activation of the receptors and opening of the NMDA receptor channel pore, 
extracellular MTSEA becomes accessible to NR1(A652C) and covalently modifies the 
NR1(A652C), locking open the NMDA receptor channel (Jones et al., 2002). Although, this 
method does not give the absolute POPEN of the receptors, it can report relative differences in 
channel activity. MTSEA potentiates NMDA receptor current which is inversely related to the 
channel POPEN (Erreger et al., 2004; Yuan et al., 2005). From the results obtained, co-
application of 0.2 mM MTSEA with agonists potentiated the currents for NR1(A652C)/NR2B 
to a similar degree as previously reported (Fig. 4.8A) (Yuan et al., 2005).  Application of 
MTSEA to NR1(A652C)/NR2B-ATD-K318 receptors (27.2 ± 4.90-fold, n=5) (Fig. 4.8B 
and Fig. 4.8C) produced similar degree of potentiation as compared to that of the 
NR1(A652C)/NR2B receptors (30.4 ± 2.85-fold, n=10; P > 0.05; unpaired T-test) (Fig. 4.8A 





Fig. 4.8. NR2B-ATD-K318-expressing receptors does not alter POPEN. (A) Glu/Gly 
represented glutamate (50 M) and glycine (30 M). 0.2 mM MTSEA potentiated the 
agonist-evoked NMDA receptor for NR1(A652C) co-expressed with (A) NR2B or (B) 
NR2B-ATD-K318. (C) Summary of the MTSEA potentiation of NR1(A652C)/NR2B and 
NR1(A652C)/NR2B-ATD-K318. IGG and IMTSEA represent the maximal currents evoked by 
the agonists (glutamate and glycine) and MTSEA + agonists (glutamate and glycine) 
respectively. IMTSEA/IGG responses between wild-type and NR2B-ΔATD-K318 were not 
statistically different (indicated as n.s.).  indicates value obtained from each experiment. 
Statistical test used was unpaired T-test.  n=5-10 oocytes recorded (in parentheses). Values 






4.4 Discussion  
Scenario one versus scenario two 
In this study, we have explored two possible consequences of the thrombin cleavage of NR2B 
at Lys
318
 to the NMDA receptors, i.e. consequences of the (1) missing intraprotomer disulfide 
bond on the ATD NR2B of the NMDA receptors and (2) removal of the ATD region up to 
Lys
318
 at the NR2B. In scenario one, the strategy chosen was to mutate the NR2B ATD 
cysteine residues (that are involved in the disulfide bond) to alanine and analyze the changes 
to the function of the NMDA receptors. For scenario one, the absence of the intraprotomer 
disulfide bond, as demonstrated by NR2B(C86A), NR2B(C321A) and the double mutant 
NR2B(C86A/C321A), did not appear to be crucial for the function of the NMDA receptors in 
terms of ligand binding as it did not affect the IC50 of ifenprodil and EC50 of glutamate and 
glycine (Table 4.1). This indicated that upon thrombin cleavage at Lys
318
, a change in the 
HVL structure could occur and affect the disulfide bond formation. However, the failure in 




 is not sufficient in affecting the apparent 
binding properties of the ATD and the ATD-LBD interaction. Analyzing the recent ATD 
NR2B crystal structure, the disulfide bond is located at the top of the R1, a distant away from 
the cleft for the ifenprodil binding (Fig. 4.1 top panel) (Perin-Dureau et al., 2002a; Karakas et 
al., 2009; Mony et al., 2009b). This could explain the failure to induce a change in the 
ifenprodil IC50. Although the ATD is also observed to be involved in the allosteric modulation 
of the LBD, changing the glutamate apparent binding and crucial in modulating the glycine 




 did not change 
the EC50 of glutamate and glycine (Zheng et al., 2001; Madry et al., 2007b; Gielen et al., 
2008). Inter-domain and/or inter-subunit interface was proposed to be at the bottom of the R2 
of the ATD, due to the observation of a hydrophobic patch at that region (Karakas et al., 




 at the R1 would be less effective in 
inducing a change in the glutamate and glycine EC50. These results correlated with some of 









 at NR2A, upon mutation to alanine, did not 
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significantly affect the EC50 of glutamate and glycine (Laube et al., 1993; Choi et al., 2001). 
The double mutant NR2A(C87A/C320A) was also ineffective in inducing a significant 
change in the Zn
2+
 IC50 (Choi et al., 2001). Thus upon cleavage at Lys
318
 of NR2B, 
progression to scenario one would induce minimal changes to the NMDA receptors function. 
In the second scenario, the removal of the ATD region up to Lys
318
 caused a change 
in the IC50 of ifenprodil. This correlated with our earlier results and proposition from Chapter 
3, whereby thrombin cleavage at Lys
318
 of NR2B under reducing condition and the resultant 
shift in the ifenprodil sensitivity would be due to cleavage of NR2B subunits (Fig. 3.5 in 
Chapter 3). As proposed in Chapter 3, the complete removal of the region up to Lys
318
, as 
demonstrated in this Chapter, caused an almost complete removal of the high-affinity 
ifenprodil inhibition (Fig. 4.4 and Table 4.2). Thus, we proposed that upon cleavage at Lys
318
, 
progression to scenario two could be more likely than scenario one, as scenario one did not 
induce any change in the ifenprodil IC50. However more experiments would be required to 
confirm such a hypothesis.  
 
Role of ATD in NMDA receptor function 
Removal of the ATD region up to Lys
318
 as demonstrated in scenario two also gave a glimpse 
of the importance of the ATD in the NMDA receptors.  
 
Assembly 
Unlike the ATD of NR2A and NR2B, the ATD of other iGluRs and mGluRs does not bind to 
modulators to allosterically regulate the function of the receptors. Rather, the ATD of these 
receptors, are important for the proper assembly of the receptors (Kuusinen et al., 1999; 
Leuschner and Hoch, 1999; Ayalon and Stern-Bach, 2001; Meddows et al., 2001). However, 
in our investigation, it was observed that the removal of a big portion of the ATD (NR2B-
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ΔATD-K318), functional receptors were nonetheless expressed. This correlated with earlier 
results in which the removal of the entire ATD of NR1 and NR2 are functional (Fayyazuddin 
et al., 2000; Hu and Zheng, 2005b; Madry et al., 2007a; Gielen et al., 2009; Yuan et al., 




Removing the ATD region up to Lys
318
 of NR2B (NR2B-ΔATD-K318) did not result in a 
change in the glutamate EC50 (Fig. 4.5 and Table 4.2). It was also observed previously that 
ATD deletion constructs did not influence glutamate EC50 (Madry et al., 2007a; Yuan et al., 
2009a). However using NR2 ATD chimeras, Yuan et al. (2009) observed that the ATD 
contributed to the high and low glutamate EC50 of the NR2A and NR2D respectively, 
suggesting the importance of the ATD in determining the glutamate binding. The 
discrepancies between studies of the deletion mutants and chimera mutants reflect different 
effects of experimentally modulating the intra- and inter-subunit allosteric interactions.  
It was also observed in this study that the NR2B-ΔATD-K318 also showed a 
significant increase in the EC50 of glycine. This correlated with earlier studies in which the 
removal of the ATD of NR2 subunits increases the EC50 of glycine, indicating the importance 
of NR2 regulation of glycine binding at the NR1 subunit (Madry et al., 2007a; Yuan et al., 
2009a). Recently, Sobolevsky and colleagues suggest that the NR1 and NR2, could assume a 
similar architecture as GluR2, ie. with subunits arranged in a 1-2-1-2 pattern, where there are 
intra- and inter-ATD dimer interface in a NMDA receptor complex (Sobolevsky et al., 2009). 
Thus, disrupting the ATD of NR2B via thrombin proteolytic cleavage may have upset the 
inter- and intra-domains allosteric interactions as shown by the change in EC50 glycine (Fig. 




Fig. 4.9. Model illustrating the conformational changes proposed to occur in scenario 
two. R1 and R2 form the cleft of the ATD (orange) while D1 and D2 form the cleft of the 
LBD (green). (Top panel) Upon binding of glutamate (pink) and glycine/D-cycloserine (red) 
to NR2B and NR1 respectively, the channel (gray) opens. Binding of ifenprodil (blue) at the 
ATD pulls the LBD apart and triggers the closure of the channel, inducing inhibition. (Bottom 
panel) Upon cleavage at Lys
318
 of NR2B, a truncated fragment of ATD (indicated by T) is left 
attached to the rest of the NR2B subunit. A slight change in the conformation is created due 
to the truncated ATD NR2B.  Glutmate and glycine/D-cycloserine can bind to the receptor, 
albeit in a slightly different conformation, making different interdomain or intersubunit 
contacts compared to the non-cleaved NR2B-expressing receptors (top panel). Ifenprodil 
(light blue) cannot bind to the truncated NR2B ATD and is not able to inhibit the receptor. 
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Interestingly, it was also observed that the efficacy of the the partial agonist, D-
cycloserine, specific for binding to NR1, was increased significantly when the ATD region up 
to Lys
318
 of NR2B was removed (Fig. 4.7 and Table 4.2). It is observed that the efficacy of D-
cycloserine at different NR1/NR2 subunit combinations is dependent on the NR2 subunit 
(Sheinin et al., 2001; Dravid et al., 2010). Dependency on the NR2 subtype suggests that the 
intersubunit communication must occur, which concurs with our results that the NR2B-
ΔATD-K318 resulted in a change in the D-cycloserine efficacy. However, LBD dimer 
interface interactions between the NR1 and NR2B-ΔATD-K318 could be different compared 
to NR2B, resulting in a higher relative efficacy for NR1/NR2B-ΔATD-K318 receptors (Fig. 
4.7). This change could have been induced by the shorter remaining ATD (Fig. 4.9). This 
somewhat correlated with observations by Dravid et al. (2010) that the ATD cold be one of 





It was also observed that the removal of the ATD region up to Lys
318
 did not change the POPEN 
of the receptors. However, recent data had shown that the ATD is important for the regulation 
of the POPEN and the determination of the different POPEN observed among the NR2 subunits 
(Erreger et al., 2005; Gielen et al., 2009; Yuan et al., 2009a). Looking closely at the data 
obtained in this Chapter, the discrepancies suggested that the region between Ser
319
 and the 
LBD harbors the important determinant for modulating the POPEN. Indeed, it has been 




of NR2B) works together with the ATD to control the 
gating of the NMDA receptors (Gielen et al., 2009; Yuan et al., 2009a).   
 
Clinical relevance 
Considering the importance of the ATD in regulating numerous aspects of the NMDA 
receptor function and properties, cleavage by thrombin at Lys
318
 of NR2B may be a form of 
modulation on the NMDA receptors. This is also supported by a recent report that plasmin 
cleavage at a homologous residue Lys
317
 of NR2A removes the Zn
2+
 sensitivity and shifts the 
EC50 of glycine slightly to the right, i.e. a higher EC50 of glycine (Yuan et al., 2009b). Such 
protease modification of the NMDA receptors is also observed in other protease systems. For 
example, upon overactivation of NMDA receptors, calpain, a Ca
2+
-dependent protease, 
becomes activated and cleaves the CTD of NR2 subunits, regulating the NMDA receptor 
turnover at the synapses (Dong et al., 2004; Wu et al., 2005; Bretin et al., 2006). Thus, the 
downregulation of NMDA receptors at the synapse provide a neuroprotective mechanism 
against NMDA receptor overstimulation accompanying ischemia and stroke (Gascon et al., 
2008).  
During ischemic stroke, thrombin cleavage at Lys
318
 of NR2B may also become a 
form of neuroprotective mechanism. The removal of the region before this portion of the 
ATD caused an increase in EC50 of glycine by 14-fold, i.e. from an EC50 of 0.29 ± 0.03 µM in 
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wild-type receptors to 4.27 ± 0.50 µM in NR2B-ΔATD-K318 receptors (Table 4.2). Glycine 
concentration is observed to be about 6 µM in the CSF obtained through microdialysis 
experiment (Thomson et al., 1989; Whitehead et al., 2001). However, it should be noted the 
neurotransmitter levels, such as that of glycine, are highly regulated by uptake mechanism, 
inhibitor systems and enzymatic degradation to inactive metabolites (Swartz et al., 1990; 
Russi et al., 1992; Betz et al., 2006). With that in consideration, glycine sites at the NMDA 
receptors may not be at saturation (Wilcox et al., 1996; Berger et al., 1998; Bergeron et al., 
1998; Chen et al., 2003; Hayashi et al., 2006; Li et al., 2009). Thus, it may be possible that the 
increase in glycine EC50 induced by thrombin cleavage at Lys
318
 of NR2B is a mechanism of 
protection from excitotoxicity. Bearing in mind that the endogenous NR1 binding ligand in 
the brain is D-serine, it would be interesting to investigate if cleavage at the Lys
318
 could 
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129 
 
5 Conclusion and future studies  
5.1 Conclusion 
In this thesis, the interaction between the serine protease thrombin and the NMDA receptors 
and the possible consequences of the interaction were studied (Fig. 5.1). Firstly, by using 
RBL and SPM as the NMDA receptors sources, the interaction between thrombin and the 
NR2B subunit was determined. The interaction was in the form of direct and specific 
cleavage of NR2B by thrombin. Using site directed mutagenesis on the recombinant MBP-
ATD2B protein and N-terminal sequencing of the cleaved off product, the cleavage site was 
identified to be at Lys
318
 of NR2B. It was also observed that thrombin could cleave NR2B 
existing in NMDA receptors complex expressed on the membrane surface of E18 cortical 
neuronal culture. I further demonstrated, electrophysiologically, the thrombin cleavage on 
NR2B ATD using TEVC recordings on Xenopus oocytes. The reduction in ifenprodil 
inhibition upon thrombin cleavage under reducing conditions validated that thrombin cleaves 
at the ATD, affecting the apparent binding of ifenprodil to the ATD and ultimately the 
sensitivity of the cleaved receptors to ifenprodil. However, it was also observed that the 
thrombin cleavage on NR2B existing in a functional receptors was less efficient and required 
a reducing environment. By analyzing the relative position of Lys
318
 on the NR2B ATD 
crystal structure and performing a molecular dynamics simulation, we have provided insight 
into how a reducing environment exposes the Lys
318
 to the extracellular milieu allowing for 
interaction with thrombin.  
 In addition, the possible effects of the thrombin cleavage on NR2B-expressing 
receptors were explored. The deletion construct, with the ATD region up to Lys
318
 removed, 
decreases the apparent ifenprodil binding and increases the glycine EC50 and the efficacy of 
D-cycloserine. Thus the observation reported herein provides an understanding for (1) a less 
explored mechanism for the modulation of the NMDA receptors via thrombin cleavage and 










5.2 Future studies 
Based on the observations in this thesis, several areas would be of interest for future studies 
(Fig. 5.2). 
 
State of NR2B-expressing receptors after thrombin cleavage 
The study presented above proposes two possible scenarios of the NR2B-expressing receptors 
upon thrombin cleavage. One scenario demonstrates minimal disruption to the structure and 
function of the receptors when the truncated fragment remains associated to the rest of the 
receptors via bonds formed between the α-helices and β-sheets. The other scenario 
demonstrates major disruption of the structure and function of the receptors when the 
truncated fragment is completely detached away from the rest of the receptors. Our results 
from Chapter 3, which demonstrate a decrease in ifenprodil sensitivity (Fig. 3.5), suggested 
that the second scenario may be more probable (Fig. 4.1 in Chapter 4). However, more 
experiments will be needed to verify these observations (Fig. 5.2). As described previously in 
this study, it would be optimal to identify protease cleavage when the substrates are in their 
native forms. NR2B from cortical neuronal cells or NR2B co-transfected with NR1 in cell-
lines can act as substrates. Upon thrombin cleavage, if the ATD region up to Lys
318
 of NR2B 
is detached away from the receptors, it will be shed and will accumulate in conditioned 
medium. The conditioned medium could be analyzed for the presence of the cleaved off 30 
kDa through liquid chromatography (Overall and Blobel, 2007).  
What is the fate of the 30 kDa that has been shedded off? Is it targeted for 
degradation? Or would it present as a likely antigen for the generation of autoantibodies 
against the NMDA receptors (Fig. 5.2)? NMDA receptors autoantibodies have been observed 
in the CSF and serum of patients suffering from encephalitis, systemic lupus erythematosus 
(SLE), epilepsy and craniocerebral trauma (Boldyrev et al., 2004; Miglio et al., 2005; 
Goryunova et al., 2007; Efthimiou and Blanco, 2009; Gable et al., 2009; Kashihara et al., 
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2009; Sorokina et al., 2009; Zandi et al., 2009; Hughes et al., 2010; Irani et al., 2010). These 
autoantibodies recognize the extracellular domain of the NR1 and/or NR2 subunits, with 
exception to the autoantibodies from Rasmussen’s encephalitis which recognize the CTD 
(Shefner et al., 1991; Katz et al., 1994; Gaynor et al., 1997; Takahashi et al., 2005; Dalmau et 
al., 2007; Steup-Beekman et al., 2007; Arinuma et al., 2008; Dalmau et al., 2008). The 
production and the presence of the autoantibodies correlate with the development of the 
diseases (Dambinova et al., 2002; Ishikawa et al., 2007; Irani et al., 2010). The autoantibodies 
produced from the diseases bind to the NMDA receptors resulting in differential effects. For 
example, autoantibodies from encephalitis bind to NMDA receptors and reversibly reduce the 
number NMDA receptors at the synapse while binding to autoantibodies from SLE causes 
neuronal death. These actions contribute to the neurobehavioral and cognitive impairment 
observed in encephalitis or SLE patients (DeGiorgio et al., 2001; Omdal et al., 2005; Kowal 
et al., 2006; Lapteva et al., 2006; Levite and Ganor, 2008). The mechanisms for the 
production of these antibodies may involve two possible ways. (1) Memory B cells are 
postulated to cross the blood brain barrier and are able to undergo restimulation, antigen-
driven affinity maturation, clonal expansion and differentiation into antibody-secreting 
plasma cells (Hauser et al., 2008). (2) Like in encephalitis which has paraneoplastic 
manifestation of a tumor, such tumor expresses neuronal proteins such as NMDA receptors, 
resulting in production of autoantibodies. These autoantibodies enter the CNS when the blood 
brain barrier is compromised (Kowal et al., 2006). Interestingly, autoantibodies are also 
observed from the serum of patients suffering from transient ischemic attack and ischemic 
stroke. These antibodies recognize the extracellular domain (Dambinova et al., 1998; 
Dambinova et al., 2002; Dambinova et al., 2003; Saenger and Christenson, 2010). Thus 
would the 30 kDa be one of the antigens for the production of autoantibodies in ischemic 
stroke? This could be investigated by collecting serum samples, or possibly CSF samples, 
from rat ischemic stroke model or patients suffering from ischemic stroke. As previously 
discussed in the Discussion section in Chapter 3, the rat ischemic stroke model that mimic 
closely to a focal embolic stroke would be optimal. Focal embolic stroke model can be 
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performed by the injection of a pre-formed clot into middle cerebral artery (MCA) (Wang et 
al., 2001; Wang et al., 2003). This may take into account of thrombin cleavage on NMDA 
receptors. Serum or CSF collected from these ischemic model rats can be analyzed using 
liquid chromatography for the presence of the 30 kDa fragment antigen. The analysis for the 
presence of autoantibodies can also be performed using immunohistochemistry with rat and 
human brain, immunostaining of live, non-permeabilized neuronal cultures and 
immunolabeling of human embryonic kidney 293 (HEK293) cell-lines transfected with 
NR1/NR2B and NR1/NR2B-ΔATD-K318. These methods are used previously for the 
identification of autoantibodies in CSF of encephalitis patients (Dalmau et al., 2008; Hughes 
et al., 2010).  
 In the case that the ATD region up to Lys
318
 is completely removed, leaving the 
remaining 150 kDa localized on the surface membrane, what is the relative stability of this 
population of receptors as compared to an uncleaved NR2B-expressing NMDA receptors 
(Fig. 5.2)? Although the internalization motif of the NR2B is located in the CTD, it is 
observed that glycine can prime the NMDA receptors for internalization by binding to the 
LBD of the NMDA receptors (Roche et al., 2001; Nong et al., 2003). Compared to the glycine 
concentration required for activation of the NMDA receptors, that required for the priming 
effect is 20-100 times higher (Nong et al., 2003). The removal of the ATD region up to Lys
318
 
of the NR2B ATD increases the EC50 glycine possibly through a change in the interaction 
between the ATD and LBD domain of NR1 and NR2B (in an intrasubunit or intersubunit 
interacting manner). Would the priming effect be altered in a similar way? If the glycine 
priming effect is altered, does it affect the endocytosis of these cleaved, truncated receptors? 
These effects can be first investigated by electrophysiology. For example, whole cell voltage 
recording can be performed on NR2B-ΔATD-K318-expressing receptors expressed on 
HEK293 cells or oocytes that had been primed with glycine, followed by exposure to agonist 
stimulation over several minutes. Observation can be made, investigating if such glycine 
priming induces a rapid, use-dependent rundown of NR2B-ΔATD-K318-expessing NMDA 
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receptors similar to that of the wild-type NR2B-expressing receptors (Vissel et al., 2001). The 
mEPSCs, particularly the NMDA receptor component, can also be measured upon thrombin 
cleavage on hippocampal neurons from primary culture, to investigate if cleaved synaptic 
NMDA receptors are internalized in a different manner (Nong et al., 2003; Prybylowski et al., 
2005). Such cultures can be obtained from PAR-1 knockout mice to exclude the indirect 
effects from PAR-1 on NMDA receptors (Lee et al., 2007). This allows solely the study of the 
possible effects of thrombin cleavage on NR2B-containing NMDA receptors endocytosis. 
Recent evidences have shown the importance of ATD of the NR2 subunits in the 
modulation of the channel kinetics, such as deactivation time courses, mean open and the 
POPEN (Gielen et al., 2009; Yuan et al., 2009a). In this study, it was demonstrated that the 
POPEN of NR1/NR2B-ΔATD-K318 was not statistically different from that of wild-type 
NR1/NR2B receptors (Fig. 4.8). This correlated with studies that the ATD, together with the 
linker between the ATD and S1 of the LBD, are crucial in determining the POPEN (Gielen et 
al., 2009). Thus, how would the deactivation rate and mean open duration be changed for the 
NR2B-expressing NMDA receptors if the region before the Lys
318
 of NR2B is removed by 
thrombin (Fig. 5.2)? Will these properties be unchanged, similar to that of the POPEN, since the 
linker between ATD and the S1 of the LBD remains intact in the NR2B-ΔATD-K318? How 
will the overall current density of the receptor be affected? These questions can be answered 
through electrophysiology recordings. One of which is single channel recordings from 
outside-out patches expressing NR1/NR2B-ΔATD-K318 for the investigation of current 
density, the mean open duration and the deactivation time course (Das et al., 1998; Zhang et 
al., 2008; Yuan et al., 2009a).  
 
Importance of ATD 
The electrophysiological data that are obtained using the NR1/NR2B-ΔATD-K318 receptors 
demonstrated that, through a disruption in the ATD (in the form of removing the first 318 
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residues of the NR2B ATD), the interaction between the LBD of NR1 and its ligands are 
altered. This suggests that in addition to binding to the allosteric modulators such as 
ifenprodil, ATD of the NR2B can affect agonists binding to NR1(Madry et al., 2007a). This 
may involve intrasubunit or intersubunit interactions yet identified (Fig. 5.2). These 
information can be more clearly refined with the generation of heteromeric crystal structure 
similar to that generated for GluR2 (Sobolevsky et al., 2009). Currently, the only available 
structure of the NMDA receptors that can give an insight on the subunit interaction is the 
heterodimer crystal structure of the NR1 and NR2A LBD (Furukawa et al., 2005). This does 
not give information on which part of the NR2B ATD is crucial in the interaction and affects 
the NR1 LBD. However, homology modeling and electrophysiological data can provide an 
indication of the interface involved (Chen et al., 2005; Kaczor et al., 2009). Homology 
modeling can give an idea of the possible sites of interaction. Site of interaction at the ATD 
can be confirmed through site-directed mutagenesis. Changes in the glycine binding, 
demonstrated by the glycine EC50 through electrophysiological means, can be analyzed from 
such mutants. For example, the hydrophobic patch at the NR2B R2 may be involved in the 
interdomain or intersubunit interaction (Karakas et al., 2009). Residues at this region can be 
mutated to hydrophilic residues and any changes in the EC50 glycine may confirm this region 
as mediators of allosteric regulation. Engineered disulfide bridges introduced at appropriate 
positions in the form of cysteine pairs can also identify possible sites of interaction 
(Sobolevsky et al., 2002a; Furukawa et al., 2005; Blanke and VanDongen, 2008; Sobolevsky 
et al., 2009). Such cysteines are easily manipulated through redox action or the introduction 
of bulky thiol-modifying agent such as MTSEA. These manipulations can easily alter the 
state of interaction and will aid in the study intersubunit or intradomain interactions and how 
NR2B ATD modulate the NR1 LBD in agonist binding (Gielen et al., 2008). 
Other than playing a role in modulating the pharmacological properties and the 
channel kinetics of the NMDA receptors, the ATD may be involved in non-ionotropic 
properties of the receptors (Dalva et al., 2000; Madry et al., 2007a; Gielen et al., 2009; Yuan 
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et al., 2009a). Evidences have suggested that the ATD of NR1 is involved in interacting with 
ephrinB receptors (EphB). Upon stimulation by the ligand ephrinB, postsynaptically localized 
EphB interacts with the ATD of the NR1, resulting in clustering of the NMDA receptors 
through the redistribution of NR1 receptors at the synapse (Dalva et al., 2000; Grunwald et 
al., 2001; Henderson et al., 2001). Clusters are usually the initiation of synapse formation 
(Rao et al., 1998). EphB also leads to potentiation of the NMDA receptors and the ultimate 
enhancement of the NMDA receptor gene expression through tyrosine phosphorylation of the 
Src family of tyrosine kinases (Takasu et al., 2002).  This indicates that the ATD of NR1 may 
be a crucial determinant for the interaction with extracellular molecules that may affect 
synapse formation, maturation and plasticity (Grunwald et al., 2001; Henderson et al., 2001; 
Grunwald et al., 2004). Recently, the ATD of GluRδ2, another member of the glutamate 
receptor family (orphan receptor), is also observed to interact with the extracellular molecule 
Cbln1 (from granule cells) for forming synapses in vitro and in vivo (Kakegawa et al., 2009; 
Matsuda et al., 2010; Matsuda and Yuzaki, 2010). Moreover, the absence of the ATD, 
induced by MMP-7 cleavage at the LBD domain of NR1, resulted in the translocation of 
NMDA receptors, an indication that proteases cleavage may modulate the location of NMDA 
receptors at the synapse and eventually affect synapse formation (Szklarczyk et al., 2008). 
Does thrombin have the similar effect in modulating synapse formation through the cleavage 
of NR2B at the ATD (Fig. 5.2)? This can be investigated using confocal microscopy 
techniques and electron microscopy for observing the changes in synapse formation upon 
changes in the ATD induced by thrombin. Alternatively, the ATD region up to Lys
318
 can be 
fused to the immunoglobulin Fc fragment. This enables the coupling of the ATD to protein G 
beads. If such beads colocalize with presynaptic marker such as synapsin or FM4-64, it may 





Relative importance activation of PAR-1 versus cleavage on NR2B of NMDA receptors 
The modulation of the NMDA receptors by thrombin can occur via two mechanisms. One is 
via the activation of the PAR-1 receptors at the astrocytes resulting in release of astrocytic 
glutamate. The glutamate then activates the NMDA receptors and may potentiate of the 
perisynaptic NMDA receptors (Gingrich et al., 2000; Lee et al., 2007). This is the indirect 
pathway. The study presented here demonstrates the direct pathway whereby cleavage of the 
NR2B affected the ifenprodil inhibition (Fig. 4.4). The removal of the region before the 
cleavage site (Lys
318
) of NR2B also changes the agonist and partial agonist binding to NR1 
(Fig. 4.6 and Fig. 4.7). The indirect pathway involves the activation and potentiation of the 
receptors while the direct pathway involves the increase in glycine EC50 of the NMDA 
receptors and results in the NMDA receptors requiring higher concentration of glycine for 
activation. The two pathways exhibit opposite effects on the NMDA receptors and may affect 
the amount of Ca
2+
 influx through the NMDA receptors in opposing ways. What is the 
significance of each pathway? Does one pathway favor over the other? How would the 
excitotoxicity and the outcome of ischemic stroke be affected through the different 
progression of pathway (Fig. 5.2)? One pathway overriding the other has also been observed 
when thrombin activates both PAR-1 and MMP in intracerebral hemorrhage but it is the 
MMP which is more prominent in inducing death (Xue et al., 2006; Xue et al., 2009). If such 
predominance of one pathway over the other exists, what governs it? Is it dependent on 
thrombin concentration? This is because PAR-1 requires a lower concentration for the 
activation of NMDA receptors compared to that required for cleavage of the NMDA receptors 
(Gingrich et al., 2000; Lee et al., 2007). We can employ the use of PAR-1 knockout mice 
neurons and neurons overexpressed with NR1/NR2B(K318A) and compare the Ca
2+
 influx 
through NMDA receptors by Ca
2+
 imaging. The excitotoxicity effects caused by the 
differential activation of the NMDA receptors can also be investigated and compared using 




Fig. 5.2. Summary of the future studies. Thrombin (maroon), PAR-1 (green), NR1 (light 
green) and NR2B (orange) are indicated and as color coded. Glu indicates glutamate (red). 
Red circles indicate glutamate from astrocytes while open, red circles indicate glutamate from 
presynaptic neuron. Glutamate is stored in vesicles (open black circles) and is released when 
vesicles fuse with the membrane. Thrombin can initiate downstream signaling through two 
pathways. One is the indirect pathway (pink) through PAR-1 activation while the other is the 
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